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ABSTRACT
I.

II.

INHIBITION OF THE MEP PATHWAY: DESIGN, SYNTHESIS AND
EVALUATION OF ISPF ENZYME INHIBITORS
SYNTHESIS OF PDE4D PARTIAL INHIBITORS AND EXPLORATION OF
ATROPISOMERIC ANALOGS
Zheng Zhang, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2014
Dr. Timothy J. Hagen, Director

This dissertation contains two major projects. The first project focused on the design
and synthesis of small molecule inhibitors of the methyl erythritol phosphate (MEP) pathway.
Known as a non-mevalonate isoprenoid biosynthetic pathway, plants and apicomplexan
protozoa such as malaria parasites use this to produce isoprenoids (terpenoids). Additionally,
most bacteria, including pathogens such as Mycobacterium tuberculosis, synthesize IPP and
DMAPP via the non-mevalonate pathway.1 Among the seven enzymes involved in this
pathway, a highly conserved enzyme is 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase
(IspF). Fragment screening hits on Burkholderia pseudomallei IspF (BpIspF) afforded the basis
for our chemistry leads, allowing the design of new potential IspF inhibitors. Three major
series of compounds were synthesized by efficient methods that allowed for exploration of the
IspF binding site and modification of the physiochemical properties. Fragment based screening
of the BpIspF enzymes performed by Dr. Darren Begley provided additional hits that
significantly expanded the diversity of the chemical cores and additional leads for the design of
novel inhibitors. Guided by the biophysical methods of surface plasma resonance (SPR), we

are able to obtain the binding potencies of compounds and generate structure activity
relationships (SAR) for the chemical series. Computational studies using the docking module
in the program SYBYL-X assisted in the exploration and visualization of potential binding
motifs and allowed the rational design of new potential BpIspF inhibitors. This work forms the
foundation for further medicinal chemistry efforts on the optimization of MEP pathway
inhibitors and the modification of existing IspF enzymatic assays.
The second project involved the development of a concise synthesis of PDE4D
allosteric modulators and applications toward the synthesis of new PDE4D inhibitors.
Phosphodiesterases (PDEs) are responsible for the hydrolysis of cAMP and cGMP and are
highly conserved in their catalytic domains of all super family members.2,3 Phosphodiesterase 4
(PDE4) is one of enzymes present in inflammatory and immune cells, which can be targeted as
potential therapeutic agent for central nervous system (CNS) and respiratory disease.4,5 As one
of the four protein isoforms, PDE4D has been intensely investigated and a series of partial
PDE4D inhibitors overcame the severe nausea side effects that were plaguing clinical PDE4
inhibitors.2 To improve the reported six-step synthesis of the PDE4D inhibitor D159687 that
had an 8% overall yield, a concise two-step synthesis was developed using sequential Suzuki
couplings that significantly increased the yield to 40% and provided a convergent synthesis that
allows for rapid analog synthesis. The convergent synthetic route developed for the PDE4D
inhibitors allowed for the synthesis of atropisomeric compounds. A method to separate the
atropisomeric PDE4D inhibitors was developed using chiral HPLC. The atropisomeric PDE4D
inhibitors will open an opportunity to study the binding modes and biological activity of these
inhibitors.
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CHAPTER 1
Background
Methyl erythritol phosphate (MEP) biosynthetic pathway
Isoprenoids, which are derived from isopentenyl diphosphate (IPP) and dimethylallyl
diphosphate (DMAPP), comprise diverse metabolites responsible for cellular functions.6 Two
distinct pathways are responsible for the production of isoprenoids. Mevalonate-dependent
biosynthetic (MAD) pathway present in plants, archaea, fungi and mammals,7 involves the
enzyme HMG-CoA reductase that has various biological effects such as protein prenylation, cell
membrane maintenance and steroid biosynthesis. Currently, statin drugs target the HMG-CoA
reductase enzyme and lower cholesterol levels for the treatment of cardiovascular disease (Figure
1).8

Figure 1 MAD biosynthetic pathway

2

Figure 2 MEP biosynthetic pathway

Compared to the MAD pathway, the MEP (methyl erythritol phosphate) pathway (Figure
2) is an alternative metabolic pathway for the synthesis of IPP and DMAPP, which is widely
present in higher plants, algae, bacteria, and malarial parasites.7 It was first discovered by Michel
Rohmer in 1990’s by a isotope labeling experiments.9 To be more specific, MEP is essential in
Plasmodium falciparum, Mycobacterium tuberculosis, Toxoplasma gondii, Burkholderia
pseudomallei, Escherichia coli, and other infectious diseases causing organisms.6,10 Enzymes
involved in the MEP pathway are considered promising targets for new anti-infective agents and
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herbicides with minimal human host toxicity. The anti-infective compound fosmidomycin was
discovered to inhibit the IspC enzyme in the MEP pathway and is currently in phase II clinical
trials in combination of clindamycin to treat malaria.6 However, enzyme selectivity,
bioavailability and increasing drug-resistance pose hurdles in developing fosmidomycin as an
effective treatment for malaria. The driving force for my research is to design, synthesize and
evaluate novel inhibitors with improved activity against enzymes in the MEP pathway, which
might lead to new anti-infective agents in the future.
Among the seven enzymes in the pathway, my research focused on 2-C-methyl-Derythriol 4-phosphate cytidyltransferase (IspD), 4-diphosphocytidyl-2-C-methyl-D-erythritol
kinase (IspE), and 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase (IspF) since we had a
number of fragment hits and more than 100 protein crystal structures that were obtained by the
Seattle Structural Genomic Center for Infectious Disease (SSGCID) that were deposited in the
Protein Data Bank (PDB). In the MEP pathway, IspD catalyzes the coupling of 2-C-methyl-Derythritol 4-phosphate (MEP) with CTP to afford 4-diphosphocytidyl-2C-methyl-d-erythritol
(DCP-ME). The CDP-ME is then converted to 4-diphosphocytidyl-2-C-methyl-D-erythritol 2phosphate (CDP-MEP) by IspE. Finally, CDP-MEP is cyclized via IspF catalysis to afford 2-Cmethyl-D-erythritol 2,4-cyclopyrophosphate (MEcPP).

Fragment-based screening of targets involved in MEP pathway
In medicinal chemistry, various screening strategies are applied to discover new chemical
classes that are capable of binding to and inhibiting enzyme targets. Fragment based screening
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methods are known to be an effective approach for early stage drug development. The fragments
are generally molecules with molecular weights lower than 300 Da.11 Fragment screening used
and synthetic approaches which follow three key steps. The steps include fragment library
design, fragment screening and fragment elaboration cycle.11 The first example that successfully
used a fragment screening approach that resulted in a FDA approved medicine was Zelboraf.12 In
our research, the fragment based screening method offers a rational and validated approach to
proceed from a small fragment hit, usually a molecule with millimolar activity, to the discovery
of potential lead molecules with high ligand efficiency and micromolar affinity for the enzyme.
To start the screening process, our collaborators at Emerald Biostructures obtained X-ray
crystallographic information for enzymes within the MEP pathway and ligand-bound complex
structures. All the ligands can be considered as fragment hits and offered rational structureguided drug design.13 Although a variety of fragment screening methods such as ligand-based
NMR, surface plasma resonance (SPR), and calorimetry can be used to generate fragment hits,
problems still exist in these methods including inadequate binding specificity and deficiency of
structural information, respectively.13 By contrast, fragment screening by X-ray crystallography
provides direct target-hit details and provides structural information for the binding site. Typical
fragment molecules are less than 300 Da which show great per-atom binding efficiency despite
the fact of weak overall affinity.14,15 As an early stage of compound screening, our goal was to
quickly determine the potential hits and generate a library for further hit to lead optimization.
Additionally, fragment screening by X-ray crystallography of small molecules can also can be
used to locate the “hot spots” inside the protein with energy optimization. This technique
remains a challenge for larger molecules selected by high-throughput screening (HTS) due to
their extra bulk and steric effects.13 To take advantage of this method, Dr. Darren W. Begley
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from Emerald Biostructures performed the screening of enzymes from MEP pathway beginning
with fragment library screening followed by target selection (restricted by Rule of 311 criteria,
including MW < 300, hydrogen bond donor and receptor < 3, partition coefficient (LogP) < 3),
crystal growth and crystal soaking.13 In the end, structural data was collected and binding site
interactions were analyzed. Shown below are fragment hits that were found to bind to BpIspF10
(Figure 3).

Figure 3 Fragment hits for BpIspF

Sequence analysis reveals over 30% identity for IspF proteins across prokaryotic and
eukaryotic species with high conservation within the substrates binding site.13,16 B. pseudomallei
IspF (BpIspF) was chosen for the fragment screening due to its ability for crystal formation with
ligands.13 Two major binding sites were identified; those containing the cytidine and zinc sub
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pockets. Cytidine, CMP, CDP and CTP can bind to the cytidine pocket and mimic the native
substrate, 4-diphospho-cytidyl-2-C-methyl-D-erythritol 2-phosphate.13,17 Several heteroatom
containing aromatic molecules show interactions with the zinc atom in the other pocket based on
the screening with the Fragment of LifeTM (FOL) library, a collection of compounds from
Emerald Biostructures.18
After the fragment hits was successfully generated, three methods need to be consider in
the process of fragment elaboration cycle: fragment merging, fragment linking and fragment
growing.11 In my research, I focus on the fragment linking and growing methods to rationally
design lead molecules. With two pockets successfully identified, we began to analyze the
possibility of linking the fragment hits that bound to the cytidine and zinc pockets. As described
previously in this dissertation, the theory behind fragment based screening is to build a target
ligand from separate hits. First, crystal structures showed CMP, CDP and CTP bind to the
cytidine pocket with the phosphate groups binding with the zinc ion. This technique afforded a
target lead molecule with cytosine moiety and ribose ring as a connection to various zinc binding
groups from the fragment hits, which may conformationally mimic the binding pattern of CMP,
CDP and CTP. Secondly, installation of zinc binding groups on the ribose ring of cytidine is a
facile approach from a synthetic chemistry perspective that allows the use of a common
intermediate. Further discussion for the synthesis of fusion compounds, their affinities against
BpIspF and details for the analysis of binding site will be discussed later in this dissertation.
In addition to IspF, Dr. Darren Begley (at Emerald Biostructures) was also able to
investigate IspD and IspE by applying saturated transfer difference nuclear magnetic resonance
(STD NMR).18 STD NMR is widely used for characterizing binding activity of ligands to
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proteins.18-20 It first applies a selective saturated pulse and then detects the signal differences
between the saturated ligand-protein form and the free protein form. Subtraction of these two
spectra will result in a signal which only shows the molecules that bind to the enzyme resulting
in fragment hits.19 Darren Begley was able to generate additional fragment hits by this method in
a short period of time with a minimum amount of protein. Interestingly, some chemical series
have more than one fragment hit which indicates their potential to inhibit enzymes from the MEP
pathway, even though the enzyme selectivity needs to be considered in the future for these
enzyme binding assays. Figure 4 shows the result of different chemical series as fragment hits for
three enzymes in the MEP pathway (results from Dr. Darren Begley).

Figure 4 Fragment screening hits discovered against IspD, IspE and/or IspF
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Discovery and Synthesis of Fusion Molecules as IspF Inhibitors
Introduction

We applied fragment screening as a method to initiate the design of IspF inhibitors. Two
distinct pockets were shown to be present by X-ray crystallography. Cytosine, cytidine and
cytidine phosphate derivatives are observed crystallographically in the cytidine binding pocket
while a range of chemical entities with differing orientations bind in the zinc pocket. The
observation was made that in the zinc pocket, each chemical moiety coordinates to the metal
through the nitrogen from the aromatic system.10,16 The fusion molecules, which fuse the
cytidine fragment to various zinc binding fragments, were designed as the initial targets based
upon synthetic accessibility and feasibility to test our hypothesis of fragment linking inhibitor
design. Among five target molecules, the cytidine moiety is retained while other heteroaromatic
fragments that are capable of binding to the zinc ion are attached through an amide bond.

Synthesis of IspF inhibitors

Synthesis of fusion compounds began with intermediate 1, which was synthesized
according to literature procedure in six steps from commercially available (+)-cytidine.21 Target
fusion compounds were obtained by amide formation followed by deprotection. Two different
amide coupling procedures were utilized. First, 3 was synthesized from 1 by coupling with the
commercially available acid chloride 2 (Scheme 1). Compounds 4-7 were synthesized from 1
and coupled with commercially available acids using HBTU, HOBt and Et3N followed by
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deprotection of acetonide and DMT with trifluoroacetic acid in acetonitrile/water (Scheme
2).Final products 3-7 were purified by reverse phase HPLC to yield the products as TFA salts.

Scheme 1 Synthesis of fusion taget 3

Scheme 2 Synthetic approach to prepare fusion analogs 4-7
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Surface plasmon resonance (SPR) analysis
An SPR assay (performed by Sriram Jakkaraju) was used to investigate the equilibrium
dissociation constant of compounds 4-7 for BpIspF.22 First, BpIspF was immobilized using
random amine by EDC (Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride)\NHS
(N-hydroxysuccinimide coupling to a carboxylmethyl dextran SPR slide. Second, concentration
series for each compound from 2 mM to 1.7 μM (5% DMSO) were generated by serial dilution
and injected over the IspF surface. Additionally, buffer-only injections were introduced between
every compound injection. Finally, Scrubber (BioLogic Software) was used to process the data
with double referencing (subtraction of buffer-only injection and reference flow cell). The
binding responses which were recorded as a function of time allow equilibrium to be established.
KD values were obtained by fitting the data to a 1:1 Langmuir binding model.
Cytidine diphosphate (CDP) was chosen as a reference and resulted in an observed KD of
75 μM, which was close to the KD determined by Ramsden for IspF from E. coli.22 Fusion
compounds had an observed KD from 70 to 200 μM without the diphosphate group which was
recognized as essential interactions for CDP to bind to the zinc in the active site. Besides all five
fusion molecules, two fragment hits (FOL717 and FOL955) were also tested to compare their
affinity with fusion compounds. Additionally, docking scores were generated by Sybyl software
and served as a computational evaluation based on conformational energy minimization,
hydrogen bindings and other potential interactions of fusion compounds in the active site of
BpIspF. Larger docking scores indicated compounds with better calculated binding interactions.
Interestingly, the calculated scores showed a general correlation with the observed affinity values
(Table 1).
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Table 1 SPR assay (performed by Sriram Jakkaraju) and docking results (performed by Joy Blain)

Compound

BpIspF KD (μM)

Docking score

CDP

75

N.A.

3

180

8.11

4

148

8.34

5

70

8.91

6

200

7.13

7

90

8.45

FOL717

135

N.A.

FOL955

>500

N.A.

Structural analysis by computational methods
To further analyze the interactions of the fusion molecules, co-crystal structures were
obtained for two out of five lead compounds (3 and 5) with BpIspF (Dr. Darren Begley)
Alignment of crystal structures confirmed our design strategy. Compound 3 was first
investigated by overlapping it with fragment FOL 8395 (Figure 5).
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2

1

Figure 5 Crystal structures of BpIspF which contains compound 3 (in green) and FOL8395 (in cyan)
overlaid (PDB: 3KE1 and 3JVH).

Generally, the cytosine moiety will fit into the cytidine pocket through the hydrogen
bonding by the amino and carbonyl group (labeled in Figure 4 as 1 and 2). On the other side of
the ligand, hetero atom (N atom in all the cases) binds to the zinc (showed as dark sphere), which
is also coordinated to two histidine residues (His44, His10 and Asp10). The hydroxyl groups of
the ribose ring have hydrogen bonding to aspartic acid (Asp58). The cytosine moiety of
compound 3 interacts with Ala102, Pro105, Ala108 and the pyridyl nitrogen binds directly to the
zinc. Next, we investigated the crystal structure of compound 5 aligned with FOL717 in the
active site (Figure 6). In this case FOL717 interacts with the zinc by the nitrogen on the
imidazothiazole core directly while the nitrogen on the imidazothiazole moiety of compound 5
binds to the zinc through a water molecule. A similar KD value is observed for 5 as compared to
CDP and it is even higher then compound 3 which has direct interaction with zinc. Two
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hypotheses can be made: (1) Other heteroatom containing moiety can still interact with the zinc
rather than the phosphate group in CDP (2) The increase of binding affinity indicates that
bicyclic group of compound 5 creates a potential hydrophobic interaction with the pocket made
by Ile59, Phe63 and Leu78, which is above zinc in the BpIspF active site.

Figure 6 Crystal structures of compound 5 (in green) and FOL717 (in cyan) in BpIspF overlaid (PDB:
3Q8H and 3IKF).

To further study the hydrophobic interaction, molecular docking was performed using
SYBYL X-2.0. We first prepared the entry of crystal structure of compound 5 (PDB: 3Q8H) and
then use Surflex-Dock Geom to introduce free ligand of compound 7. All water molecules were
removed and the optimized binding was proposed by minimizing the binding energy
computationally. As the predicted and experimental binding modes showed, main differences are
found in the ribose ring and the zinc binding site although cytidine binding pose remains
constant and the hydrophobic interaction preserved. With the result from the computational
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study, we hypothesized that this hydrophobic interaction is essential for design of the future lead
molecules (Figure 7).

Figure 7 Crystal structures of compound 5 (in cyan, PDB: 3Q8H) and docking pose of compound 7 (in
green) overlaid.

Anti-bacterial and anti-malarial assay
In addition to the SPR assay, anti-bacterial test against Burkholderia thailandensis and
anti-malarial test against Plasmodium falciparum D6, C235, W2 strains (drug resistant strains)
were performed according to reported method.23-25 B. thailandensis was chosen for the in vivo
anti-bacterial assay of fusion compounds because it does not require biosafety level 3 (BSL-3)
facility.23,26 and its IspF enzyme displays 98% sequence identity at the nucleotide level with B.
pseudomallei. We collaborated with Dr. Peggy Cotter at the University of North Carolina at
Chapel Hill to perform the assay and all the fusion compounds are determined as inactive at the
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highest concentration (1mM). Additionally, through collaboration with Dr. Richard Sciotti at the
Walter Reed Army Institute of Research (WRAIR) the fusion compounds were assayed against
Plasmodium falciparum D6 (chloroquine sensitive but mefloquine resistant), C235 (multiple
drugs resistant) and W2 (chloroquine resistant but mefloquine sensitive).24 Plasmodium
falciparum is the most dangerous malaria parasite with highest rate of mortality and increasing
drug resistance. By targeting these strains we could evaluate the effectiveness of fusion
compounds and compare their IC50 values to the known anti-malarial agent such as mefloquine
and chloroquine. The results showed greater than 40 μM across all three strains for fusion
compounds which are considered as weak affinity compared to sub-micromolar affinity of
Mefloquine and Chloroquine.27 The anti-bacterial and anti-malarial data may result from the
negative LogP of the compounds which forbids them to penetrate the lipophilic cell wall and
reach the desired target enzyme. Further optimization on the structure of the fusion compounds is
in progress.

Conclusion
To summarize, we successfully generated five fusion compounds which were synthesized
based on the fragment hits. In order to test the hypothesis that a fragment linking approach would
lead to more potent IspF ligands, fusion molecules were designed. The fusion molecules linked
a cytidine and five different zinc binding groups through an amide bond. The BpIspF binding
affinity data was collected using an SPR assay. Compared to cytidine, which was only observed
with weak binding affinity (Dr. Darren Begley), the fusion compounds exhibited improvement
on the binding. Additionally, the fusion compounds also have comparable or lower KD to other
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fragment hit such as CDP, which showed 100 μM against EcIspF and 75 μM against BpIspF. All
these results confirmed our initial hypothesis for the linking of fragment hits. We were able to
perform the “hit to lead” method and build a chemical series with micromolar affinity for
BpIspF. Moreover, docking by SYBYL offers additional structural insight on the binding mode
using available protein crystal structures. We discovered a hydrophobic pocket that allows
additional interactions for compounds that bind to BpIspF and provides potential interaction for
optimizing the binding affinity. This hydrophobic pocket will be targeted in future work.

Experimental section
General methods
All commercially available reagents were used without further purification. Column
chromatography was performed on silica gel (230−400 mesh) using a Biotage Isolera One.
Reverse phase chromatography was performed utilized a Biotage SNAP Cartridge (KP-C18-HS)
on a Biotage Isolera One. The gradient consisted of two solvents:

solventA---water with

0.1%TFA and solventB---acetonitrile (100%A to 100%B over 10 min). 1H NMR and 13C NMR
spectra were recorded on an Avance III 300 MHz NMR (Bruker Biospin from Billenca, using
BBFO probe, 5 mm). Analytical HPLC were recorded on an Agilent 1100 HPLC system using a
C-18 column (Waters Nova-Pak 3.9 x 150 mm) with the following gradient: 90:10 water (0.1%
TFA) to acetonitrile to 10:90 water (0.1% TFA) to acetonitrile over 40 minutes. Samples were
monitored at 254 and 280 nm. CHN analysis was recorded on Perkin Elmer Series II CNH
analyzer.
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Surface plasmon resonance
SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF
was coupled to the sensor slide using amine coupling chemistry. Initially, the surface was
activated

by

injecting

a

dimethylaminopropyl)carbodiimide

mixture

of

hydrochloride)

75

mg/ml
and

11.5

EDC
mg/ml

(N-Ethyl-N′-(3NHS

(N-

hydroxysuccinimide) for 7 min using a 50 μl/min flow rate. IspF, diluted in 10 mM 5.0 pH
sodium acetate buffer at a final concentration of 120 μg/ml, was injected over the surface for 10
min at 30 μl/min. Excess succinamide ester groups were quenched with an injection of 1M
ethanolamine for 6 min with a 50 μl/min flow rate. A total of 4000-7500 μRIU (Refractive index
units) of IspF were coated on the slide. Binding experiments were conducted at 20°C in 50 mM
sodium phosphate pH 7.4/150 mM NaCl/4.76% DMSO at 50 μl/ min. Initially, compounds were
dissolved in DMSO at 20 mM and were diluted (20-fold) into 50 mM sodium phosphate pH
7.4/150 mM NaCl, to produce a 1 mM compound sample with 4.76% DMSO, thereby
minimizing buffer mismatch. A concentration series of compound from 1 mM to 0.8 μM (diluted
using running buffer) was generated and injected over the IspF surface. Blank (Buffer-only)
injections were included between each compound injection, allowing for double subtraction
(reference cell and buffer) during data processing. Data processing and analysis was performed
using Scrubber (BioLogic Software).

4-amino-1-((2R,3R,4S,5R)-5-(aminomethyl)-3,4-dihydroxytetrahydrofuran-2-yl)pyrimidin2(1H)-one (1): 1 was synthesized by the reported method21 and purified by column
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chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielding 1 (1.90 g, 77%). 1H NMR (CDCl3,
300 MHz): δ1.34 (s, 3H); 1.55 (s, 3H); 2.36 (s, 3H); 4.01 (dd, J = 14, 5 Hz, 1H), 4.17 (dd, J = 14,
8.5 Hz, 1H); 4.52-4.55 (m, J = 5.7, 1H); 4.97 (dd, J = 6.5, 4 Hz, 1H); 5.21 (d, J = 6 Hz, 1H); 5.63
(s, 1H); 7.50 (d, J = 7.5 Hz, 1H); 6.82-6.89 (m, 4H); 7.06 (d, J =9 Hz, 1H); 7.18-7.24 (m, 4H);
7.32-7.37 (m, 5H).

N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2yl)methyl)isonicotinamide (3): To a solution of 1 (0.33 g, 0.564 mmol) and Et3N (0.06 g, 0.564
mmol) in anhydrous DCM (10 ml) was added 2 (0.08 g, 0.564 mmol). The resulting solution was
allowed to stir for 4h at rt. The reaction mixture was then washed with brine (3 x 50 mL) and the
organic layer dried over anhydrous Na2SO4 and concentrated in vacuo. Purification by flash
chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded the protected intermediate which was
taken directly to the next step without further characterization. Starting from the protected
intermediate, CH3CN (2 ml), H2O (2 ml) and TFA (1.36 ml) were added to the reaction mixture.
The resulting solution was allowed to stir overnight at rt. The volatiles were then removed in
vacuo and the reaction mixture was subjected to reverse phase chromatograph, followed by
lyophilization yielding 3 as a white solid (0.13 g, 35%). 1H NMR(D2O, 300 MHz): δ3.73(d, J =
5.7 Hz, 2H), 4.12(m, 2H), 4.32(m, 1H), 5.65(d, J = 3.3 Hz, 1H), 6.11(d, J = 7.8 Hz, 1H), 7.85(d,
J = 8.1 Hz, 1H), 8.24(dd, J = 6.9, 1.5 Hz, 2H), 8.85(dd, J = 6.9, 1.2 Hz, 2H).
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C NMR (D2O,

300 MHz): δ41.63, 70.55, 73.23, 81.77, 92.36, 94.90, 125.35, 142.41, 144.96, 148.04, 150.13,
159.16, 165.56. Anal. Calcd. for C15H17N5O5• 2.5CF3COOH• H2O: C, 36.93, H, 3.33, N, 10.77.
Found: C, 36.90, H, 3.12, N, 10.49.
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N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofu
ran-2-yl)methyl)-2-(imidazo[2,1-b]thiazol-6-yl)acetamide (4): To a solution of 1 (0.30 g,
0.513 mmol) and Et3N (0.05 g, 0.513 mmol) in DMF (2 ml) was added a solution of HOBT (0.09
g, 0.513 mmol), HBTU (0.19 g, 0.513 mmol) and imidazo[2,1-b]thiazole-6-acetic acid (0.09 g,
0.513 mmol)in DMF (3ml). The resulting solution was allowed to stir overnight at rt.
Purification by flash chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded protected
intermediate which was taken directly to the next step without further characterization. Started
from the protected intermediate, CH3CN (2.5 ml), H2O (2.5 ml) and TFA (2 ml) were added to
the reaction mixture. The resulting solution was allowed to stir overnight at rt. The volatiles were
removed in vacuo and the reaction mixture was subjected to reverse phase chromatograph,
followed by lyophilization yielding 4 as a light yellow solid (0.19 g, 58%). 1H NMR(CD3OD,
300 MHz): δ3.60 (dd, J = 6.3, 4.8 Hz, 2H), 3.83 (s, 2H), 4.04 (m, 2H), 4.29 (dd, J = 5.6, 3.6 Hz,
1H), 5.73 (d, J = 3.6 Hz, 1H), 6.11 (d, J = 7.8 Hz, 1H), 7.54 (d, J = 4.2 Hz, 1H), 7.91 (s, 1H),
8.02 (d, J = 4.2 Hz, 1H), 8.06 (d, J = 8.1 Hz, 1H). 13C NMR (CD3OD, 300 MHz): δ32.03, 40.98,
70.91, 73.61, 82.66, 92.78, 93.59, 113.35, 117.18, 121.06, 134.29, 145.67, 147.37, 147.55,
160.11, 169.08. Anal. HPLC (RetTime: 2.0 min, Area%:97%).

N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2yl)methyl)imidazo[2,1-b]thiazole-6-carboxamide (5): To a solution of 1 (0.25 g, 0.428 mmol)
and Et3N (0.04 g, 0.428 mmol) in DMF (2 ml) was added a solution of HOBT (0.07 g, 0.428
mmol), HBTU (0.16 g, 0.428 mmol) and imidazo[2,1-b]thiazole-6-carboxylic acid (0.07 g, 0.428
mmol) in DMF (3ml). The resulting solution was allowed to stir overnight at rt. Purification by
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flash chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded protected intermediate which was
taken directly to the next step without further characterization. Starting from the protected
intermediate, CH3CN (2.5 ml), H2O (2.5 ml) and TFA (2 ml) was added to the reaction mixture.
The resulting solution was allowed to stir overnight at rt. The volatiles were removed in vacuo
and the reaction mixture was subjected to reverse phase chromatograph, followed by
lyophilization yielding 5 as a white solid (0.19 g, 71%). 1H NMR(CD3OD, 300 MHz): δ3.72 (dd,
J = 14.4, 6.6 Hz, 1H), 3.82 (dd, J = 14.4, 6.6 Hz, 1H), 4.09 (overlap dd, J = 5.4 Hz, 1H), 4.18
(dd, J = 10.5, 4.8 Hz, 1H), 4.31 (overlap dd, J = 5.1, 3.6 Hz, 1H), 5.75 (d, J = 3.6 Hz, 1H), 6.10
(d, J = 7.8 Hz, 1H), 7.38 (d, J = 4.5 Hz, 1H), 8.00 (s, 1H), 8.11 (d, J = 7.8 Hz, 1H), 8.34 (d, J =
4.5 Hz, 1H). 13C NMR (CD3OD, 300 MHz): δ 40.41, 70.91, 73.69, 82.90, 92.51, 93.59, 115.49,
120.79, 124.89, 127.80, 128.51, 134.42, 145.43, 147.59, 160.05, 160.15. Anal. HPLC (RetTime:
2.1 min, Area%: 94%).

N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2yl)methyl)thiazole-4-carboxamide (6): To a solution of 1 (0.25 g, 0.428 mmol) and Et3N (0.04
g, 0.428 mmol) in DMF (2 ml) was added a solution of HOBT (0.07 g, 0.428 mmol), HBTU
(0.16 g, 0.428 mmol) and 4-thiazolecarboxylic acid (0.06 g, 0.428 mmol) in DMF(3ml). The
resulting solution was allowed to stir overnight at rt. Purification by flash chromatography
(Et3N/MeOH/EtOAc = 1/10/89) yielded protected intermediate which was taken directly to the
next step without further characterization. Started from the protected intermediate, CH3CN (1.5
ml), H2O (1.5 ml) and TFA (1.3 ml) was added to the reaction mixture. The resulting solution
was allowed to stir overnight at rt. The volatiles were removed in vacuo and the reaction mixture
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was subjected to reverse phase chromatograph, followed by lyophilization yielding 6 as a white
solid (0.10 g, 40%). 1H NMR(CD3OD, 300 MHz): δ3.70-3.87 (m, 2H), 4.05 (overlap dd, J = 5.7
Hz, 1H), 4.20 (overlap dd, J = 6 Hz, 1H), 4.26 (overlap dd, J = 5.1 Hz, 1H), 5.80 (d, J = 3.6 Hz,
1H), 6.10 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 7.8 Hz, 1H), 8.29 (s, 1H), 9.03 (s, 1H).
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C NMR

(CD3OD, 300 MHz): δ 40.53, 71.03, 73.98, 82.79, 91.75, 93.74, 123.80, 144.71, 148.76, 150.25,
154.18, 160.83, 162.45. Anal. HPLC (RetTime: 2.1 min, Area%:97%).

N-(((2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2yl)methyl)-1H-imidazo[4,5-b]pyridine-7-carboxamide (7): To a solution of 1 (0.30 g, 0.513
mmol) and Et3N (0.05 g, 0.513 mmol)in DMF (2 ml) was added a solution of HOBT (0.09 g,
0.513 mmol), HBTU (0.19 g, 0.513 mmol) and 3H-Imidazo[4,5-b]pyridine-7-carboxylic acid
(0.08 g, 0.513 mmol) in DMF (3 ml). The resulting solution was allowed to stir overnight at rt.
Purification by flash chromatography (Et3N/MeOH/EtOAc = 1/10/89) yielded protected
intermediate which was taken directly to the next step without further characterization. Started
from the protected intermediate, CH3CN (2.5 ml), H2O (2.5 ml) and TFA (2 ml) was added to the
reaction mixture. The resulting solution was allowed to stir overnight at rt. The volatiles were
removed in vacuo and the reaction mixture was subjected to reverse phase chromatograph,
followed by lyophilization yielding 7 as a light yellow solid (0.10 g, 32%). 1H NMR(CD3OD,
300 MHz): δ3.90-3.95 (m, 2H), 4.14 (t, J = 4.8 Hz, 1H), 4.25 (t, J = 4.4 Hz, 1H), 4.32 (overlap
dd, J = 5.3, 3.5 Hz, 1H), 5.8 (d, J = 3.5 Hz, 1H), 6.07 (s, J = 7.8 Hz,1H), 7.9 (d, J = 5.1 Hz, 1H),
8.1 (d, J = 7.8 Hz, 1H), 8.6 (d, J = 5.0 Hz, 1H), 8.9 (s, 1H).
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Discovery and Synthesis of Imidazole IspF Inhibitors
Introduction
As described previously for the fusion series (see page 22), the fusion compounds were
generated based upon the combination of hit molecules that bind to two pockets from the active
site of BpIspF. This can be considered a fragment linking approach in the development of lead
molecules, during the elaboration cycle of inhibitor discovery.11 Alternatively, fragment growing
can also be employed as a reasonable method for the generation of lead molecules by expanding
fragment hits through synthetic efforts.11 Generally, the fragment growing method involves the
identification of a desired hit, and rational developments upon the structure of the hit are
performed with careful consideration of synthetic tractability. Since the structures of the hits for
the cytidine pocket is fairly conserved (all hits contain a cytosine moiety), we started to explore
the possibility of zinc binding molecules. With various fragment hits for the zinc pocket (shown
in Figure 3), we chose FOL955 as a possible candidate for the fragment growing method because
it could provide greater diversity of the resulting lead molecules and allows greater flexibility
concerning compound synthesis.
In the pursuit of novel inhibitors via the fragment growing method, structural information
concerning the initial hit molecules bound to the inhibitory site is crucial for the development of
lead molecules. Analysis of the X-ray crystal structure of FOL955 bound to BpIspF (PDB:
3QHD) offered insight into the design of new molecules (Figure 8). FOL955 binds to the zinc
through the nitrogen in the aromatic system and the phenol creates hydrogen binding with the
side chain of Phe63 and Asp65. By carefully investigating the binding region of FOL 955, we
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found the hydrophobic pocket, same to that discovered earlier for the fusion molecules, which is
created by residues Ile59, Phe63 and Leu78 in close proximity to the zinc pocket. This secondary
pocket can undergo potential reorientation to accommodate larger hydrophobic groups, which is
reported in various crystal structures of BpIspF16. To further elaborate the strategy of the
fragment growing method, we proposed two directions for the development of the fragment
FOL955: (1) Based on the hypothesis that interactions with the extra hydrophobic pocket could
potentially increase the affinity of the lead molecules, we can design a library of potential lead
compounds, utilizing FOL955 as the core coupled with functional groups capable of fitting in
the hydrophobic pocket, (2) The installation of groups pointing towards the cytidine pocket
occupied by FOL955 can provide a good starting point for fragment growth, presumably by
manipulating hydrogen binding to residues within the cytidine pocket. With no literature
evidence of molecules bound to residues within the hydrophobic pocket, we decided to choose
the second direction discussed above for fragment growth, while also considering the synthetic
accessibility of the designed compounds and the reported interactions (PDB: 3KE1) within the
cytidine pocket. To pursue our hypothesis, imidazole analogs were synthesized in which the N1
of FOL955 was moved to the N5 position of the imidazole ring for synthetic ease (Figure 9).
This analog permitted the synthesis of many compounds by varying the R groups to test for
binding affinity without affecting the ability of N3 to coordinate with the catalytic zinc ion in the
IspF active site, which the crystal structure of FOL955 bound to BpIspF depicts.
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Figure 8 Crystal structures of FOL955 (in green, PDB: 3QHD) in BpIspF.

Figure 9 Design of isomeric imidazole series
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Synthesis of imidazole compounds
The synthesis of the imidazole analogs was achieved via a similar synthetic pathway to
published procedures (Scheme 3).28,29 A mixture of MgSO4, triethyl amine and the corresponding
aromatic amine was stirred at room temperature for 1h, and 4-hydroxy benzaldehyde was added
and refluxed for 4 h to afford the corresponding imine. After the solvent was concentrated under
reduced pressure, MeOH, K2CO3 and TosMIC reagent were added, and the mixture was refluxed
for 2 h to afford the desired imidazole analog.

Scheme 3 Synthesis of imidazole series

Structure activity relationship (SAR) analysis
Initial SPR binding studies showed low affinity (KD > 2 mM) of FOL 955 (determined by
Joy Blain). The increasing affinity of the synthesized imidazole compounds compared to
FOL955 provides promising evidence for our fragment growing method. In order to generate
sufficient data for SAR analysis, eighteen imidazole compounds were synthesized and subjected

26

to the SPR assay against BpIspF to determine their KD, with L-tryptophan hydroxamate as an
internal control (KD = 60 μM).22

Table 2 SPR and in vivo assay of imidazole series (11-13 were synthesized by Gashaw Goshu)

KD

W2

(µM)

D6
(µM)

C235
(µM)

(µM)

>2000

> 40

> 40

> 40

9

>2000

> 40

> 40

> 40

10

>2000

> 40

> 40

> 40

11

>2000

>40

>40

>40

12

>2000

9.8

12.9

7.9

13

>2000

11.5

13.8

7.2

14

90

1.7

3.4

0.59

15

>2000

>40

>40

>40

16

1350

11.3

13.3

13.6

17

204

4.2

7.2

5.6

No.

R

8

FOL955
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As shown in Table 2, all the imidazole analogs ranged in binding affinity from 55 μM to
greater than 2000 μM. Additionally, the initial screening at 50 μM offered a scatter diagram
which provided the correlation between the compound number and response values (Figure 8).
We can easily separate the compounds into three groups of imidazole analogs; including weak (<
30 µRU), excess (> 140 µRU), and ideal target (30-140 µRU) responses. The weak response
group sets a lower limit estimate for KD values of > 200 μM while several compounds within the
excess group indicated the non-specific binding interactions with BpIspF and / or poor solubility
due to the fact of exceeding the calculated maximum µRU value. The remainder of the
compounds gave ideal KD between 20-200 μM which provided us with compounds for
reasonable SAR analysis.
Moreover, anti-malarial activity was measured by using three different strains of P.
falciparum as shown in Table 3. As previously described,25 these three strains of the P.
falciparum parasites are W2 (chloroquin (CQ) resistant, mefloquine (MFQ) sensitive), D6 (CQ
susceptible, MFQ resistant) and C235 (multidrug resistant, CQ, pyrimethamine). The efficacies
ranged from 0.59 μM to greater than 40 μM. Based upon the observed SAR a conclusion was
made: Substitution of the imidazole nitrogen with 1 or 2 carbon linkers bearing a heteroaromatic
or haloaromatic group result in compounds with IspF affinity and antimalarial efficacy.
Functional assay of imidazole analogs in P. falciparum
In order to confirm that the anti-malarial efficacy was a function of IspF inhibition,
selected imidazole analogs were tested by our collaborator, Dr. Audrey Odom. A high pressure
liquid chromatography-mass spectrometry (HPLC-MS/MS) based assay was used to confirm the
presence of DXS, IspD and IspF metabolic products following treatment with selected imidazole
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analogs 14 and 17 (Figure 10). The concentration of three enzymatic products from the MEP
pathway was evaluated. Decreasing concentration of MEcPP was observed for both compounds,
which indicated that imidazole analogs can interfere in the functionality of IspF by controlling
the level of metabolite. Interestingly, compound 17 showed an unexpected inhibition on the
upstream metabolite, DOXP, which is involved in the biosynthetic pathway of DXS. We are
currently collaborating with Dr. Odom to further study the mechanism of action of the imidazole
compounds against DXS, IspD, and IspF, and to investigate the selectivity of the inhibitors.

120
100
80

DOXP(DXP)
CDP-ME
MEcPP

60
40
20
0
No compound

15 μM
compound 14

15 μM
compound 17

Figure 10 Results of functional assay
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Structural analysis of compound 16
To further evaluate the designing strategy of imidazole compounds, crystal structure of
compound 16 in BpIspF was obtained (by Dr. Darren Begley). As shown in figure 11, compound
16 remains hydrogen bonding with side chain of Phe63, Asp65 and the nitrogen atom on the
imidazole ring coordinates to the zinc atom. The furan moiety orients toward the cytidine pocket
and has a potential to fit in the ribose binding area. Future development will focus on
modification of the furan ring in order to either create hydrogen bonding with Asp58 or obtain
analogs that have optimized interactions with the cytidine pocket.

Figure 11 Crystal structures of compound 16 (in green) in BpIspF.
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Conclusion
Based upon the fragment hit FOL955, which displayed poor affinity for the IspF enzyme,
lead molecules from the imidazole series were synthesized that displayed micromolar binding
affinity. These lead molecules demonstrated antimalarial efficacy against three strains of drug
resistant P. falciparum. The discovered leads from the imidazole series have potential for further
lead optimization against drug-resistant malaria strains. In addition, the HPLC-MS/MS results
demonstrated for the first time that the antimalarial efficacy was through regulation of the level
of MEcPP in cells. The functional relevance of these compounds to the in vivo assay provides
promising evidence for MEP pathway inhibition and regulation. In summary, the fragment
growing method was successfully applied in the development of the imidazole series of
inhibitors against IspF and afforded a compound library for future study. We are currently
working on the fragment growing method of other chemical motifs, which involves investigating
interactions with the hydrophobic pocket in order to increase the diversity of the imidazole
compounds.

Experimental section
All commercially available reagents were used without further purification. Column
chromatography was performed on silica gel (230−400 mesh) and Biotage Isolera One. 1H NMR
and 13C NMR spectra were recorded on Avance III 300 MHz NMR (Bruker Biospin from
Billenca, using BBFO probe, 5 mm). IR spectra were recorded on Mattson Gausis ATI FT-IR
(600 – 4000 cm-1). Melting points were recorded on Mel-Temp II from Laboratory Devices inc.,
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USA. Analytical HPLC were recorded on an Agilent 1100 HPLC system using a C-18 column
and 90:10 water(0.1% TFA) to acetonitrile ->10:90 water (0.1% TFA) to acetonitrile over 40
minutes Analytical HPLC were recorded on an Agilent 1100 HPLC system using a C-18 column
(Waters Nova-Pak 3.9 x 150 mm) with the following gradient: 90:10 water(0.1% TFA) to
acetonitrile to 10:90 water (0.1% TFA) to acetonitrile over 40 minutes. Samples were monitored
at 254 and 280 nm. CHN analysis was recorded on Perkin Elmer Series II CNH analyzer.

Surface plasmon resonance

SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF
was coupled to the sensor slide using amine coupling chemistry. Initially, the surface was
activated by injecting a mixture of 75 mg/ml EDC (N-Ethyl-N′-(3-dimethylaminopropyl)
carbodiimide hydrochloride) and 11.5 mg/ml NHS (N-hydroxysuccinimide) for 7 min using a 50
μl/min flow rate. IspF, diluted in 10 mM 4.5 pH sodium acetate buffer at a final concentration of
120 μg/ml, was injected over the surface for 7 min at 30 μl/min. Excess succinamide ester groups
were quenched with an injection of 1M ethanolamine for 3 min with a 50 μl/min flow rate. A
total of 4000-8000 μRIU (Refractive index units) of IspF were coated on the slide. Binding
experiments were conducted at 20°C in 50 mM sodium phosphate pH 7.4/150 mM NaCl/4.76%
DMSO at 50 μl/ min. Initially, compounds were dissolved in DMSO at 4 mM and were diluted
(20-fold) into 50 mM sodium phosphate pH 7.4/150 mM NaCl, to produce a 200 μM compound
sample with 4.76% DMSO, thereby minimizing buffer mismatch. A concentration series of
compound from 200 μM to 6.25 μM (diluted using running buffer) was generated and injected
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over the IspF surface. Blank (Buffer-only) injections were included between each compound
injection, allowing for double subtraction (reference cell and buffer) during data processing. Data
processing and analysis was performed using Scrubber (BioLogic Software).

Malaria parasite culture

P. falciparum strain 3D7 was cultured at 37°C in a 2% suspension of human erythrocytes
in RPMI-1640 medium (Sigma-Aldrich, SKU R4130) supplemented with 27 mM sodium
bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxanthine,
0.01 mM thymidine, 10 µg/mL gentamicin, and 0.5% Albumax (Life Technologies) in a 5% O2/
5% CO2 / 90% N2 atmosphere, as previously described.

6,30

Culture growth was monitored by

microscopic analysis of Giemsa-stained blood smears.

Metabolic profiling of MEP pathway intermediates

P. falciparum strain 3D7 was cultured in 75 mL volumes in 150 mm × 25 mm tissue
Culture dishes at 4% hematocrit until >6% parasitemia was reached. Cultures were synchronized
by 1-2 treatments with 5% sorbitol until >8% parasitemia and >75% of parasites were in ring
stage growth. Once these criteria were met, 75 mL cultures were split into 3 × 25 mL samples.
Ring stage cultures were then treated +/- 5 µM FSM (Life Technologies) for either 0 h or 10 h.
At each time point, parasite-infected erythrocytes were lysed with 0.1% saponin, the parasite
pellets washed with PBS, and the pellets stored at -80°C until extraction. Samples were extracted
and analyzed by LC-MS/MS as previously described.
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General procedure for the synthesis of imidazole analogs

Novel compounds were synthesized similarly to reported methods28,29 A mixture of the
corresponding primary amine (3.41 mmol), MgSO4 (1.03 g, 8.53 mmol) and triethylamine (3.1
mL) was stirred at room temperature for 1 hour. Then, 4-hydroxybenzaldehyde (0. 415 g, 3.40
mmol) was added, and the mixture was refluxed at 90oC for 4 hours. The reaction mixture was
filtered using section filtration, and the precipitate was washed with 10 ml Et3N followed by 10
mL anhydrous MeOH, and the solvents were removed under vacuum.
The concentrated mixture of the imine was re-dissolved in anhydrous MeOH (6 mL).
TosMIC (p-toluenesulfonyl) methyl isocyanide (0.860 g, 4.43 mmol) and K2CO3 (1.41 g, 10.2
mmol) were added, and the mixture was refluxed at 65oC for 2 hours. The solvent was removed
under vacuo, and the crude was partitioned between EtOAc (20 mL) and water (20 mL). The
aqueous layer was extracted two times with EtOAc (2 x 20 ml). The combined organic layers
were washed with brine (30 mL) and dried with anhydrous Na2SO4 (about 3 g), and the solvent
was removed at reduced pressure. The crude was chromatographed by Biotage (DCM:MeOH) to
afford the corresponding imidazole analogue. For surface Plasmon resonance (SPR) test,
compounds were converted to the corresponding hydrogen chloride salts by adding two
equivalents of HCl in dioxane. The formation of the salt was confirmed by a downfield chemical
shift of imidazole protons (see the proton NMR of the salts).
4-(1-isopropyl-1H-imidazol-5-yl)phenol (9):
The desired product was collected as a light yellow solid (0.59 g, 56.7% yield). mp 170 - 175 °C.
1

H NMR (300 MHz, CD3OD): δ 1.43 (d, J = 6.9 Hz, 6H), 4.41 (sep, J = 6.6 Hz, 1H), 6.84 (d, J =
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0.9 Hz, 1H), 6.88 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 1.2 Hz, 1H);

13

C

NMR (75 MHz, CD3OD): δ 22.54, 46.91, 115.21, 120.60, 125.37, 130.56, 132.97, 133.95,
157.71. Anal. HPLC (Ret time: 1.9 min, Area%: 99%). Anal. Calcd for C12H14N2O • 0.3H2O: C,
69.41; H, 7.09; N, 13.49; Found: C, 69.80; H, 6.98; N, 13.25.

4-(1-benzyl-1H-imidazol-5-yl)phenol (10):
The desired product was collected (0.46 g, 66.6% yield) as a light yellow solid. mp 156 159 °C. 1H NMR (300 MHz, CD3OD): δ 5.22 (s, 2H), 6.79 (d, J = 8.7 Hz, 2H), 6.95 (d, J = 1.2
Hz, 1H), 6.98 (dd, J = 7.8, 2.1 Hz, 2H), 7.11 (d, J = 8.7 Hz, 2H), 7.26-7.29 (m, 3H), 7.76 (d, J =
0.9 Hz, 1H); 13C NMR (75 MHz, CD3OD): δ 48.23, 115.09, 120.20, 125.91, 126.49, 127.40,
128.37, 130.24, 133.77, 137.99, 157.64. Anal. HPLC (Ret time: 2.6 min, Area%: 99%). Anal.
Calcd for C16H14N2O • 0.6H2O: C, 73.60; H, 5.87; N, 10.73. Found: C, 73.85; H, 5.51; N, 10.76.

4-(1-(4-chlorophenethyl)-1H-imidazol-5-yl)phenol (14)
The desired product 17 was collected as a yellow solid (0.23 g, 46.2% yield). mp 150 - 155°C.
1

H NMR (300 MHz, CD3OD): δ 2.81 (t, J = 6.9 Hz, 2H), 4.27 (t, J = 6.9 Hz, 2H), 6.84 (s,1H),

6.86 (d, J = 6.0 Hz, 2H), 6.89 (d, J = 5.4 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz,
2H), 7.48 (s, 1H); 13C NMR (75 MHz, CD3OD): δ 35.76, 46.09, 115.23, 120.45, 125.77, 128.15,
129.95, 130.07, 132.19, 133.28, 136.42, 137.64, 157.65. Anal. HPLC (Ret time: 4.8 min,
Area%: 99%). Anal. Calcd for C17H15ClN2O • 0.2H2O: C, 67.53; H, 5.13; N, 9.26; Found: C,
67.35; H, 5.19; N, 9.24.
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4-(1-(4-hydroxyphenethyl)-1H-imidazol-5-yl)phenol (15)
The desired product 18 was collected as a yellow solid (0.30 g, 48.1% yield). mp: 225 - 228°C.
1

H NMR (300 MHz, CD3OD): δ 2.72 (t, J = 6.9 Hz, 2H), 4.18 (t, J = 6.9 Hz, 2H), 6.64 (d, J = 8.7

Hz, 2H), 6.74 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 0.9 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 7.16 (d, J =
8.7 Hz, 2H), 7.44 (d, J = 1.2 Hz, 1H);

13

C NMR (75 MHz, CD3OD): δ 35.67, 46.68, 114.88,

115.19, 120.61, 125.61, 128.32, 129.32, 130.16, 133.26, 137.59, 155.87, 157.58. Anal. HPLC
(Ret. time: 2.2 min., Area%: 99%). Anal. Calcd for C17H16N2O2 • 0.2H2O: C, 71.91; H, 5.82; N,
9.87; Found: C, 72.04; H, 6.04; N, 9.90.

4-(1-(furan-2-ylmethyl)-1H-imidazol-5-yl) phenol (16)
The desired product was collected as a yellow solid (0.46 g, 61.9% yield). mp: 129 - 131°C; FTIR cm-1; 1H NMR (300 MHz, CD3OD) δ 5.16 (s, 2H), 6.14 (dd, J = 3.3, 0.6 Hz, 1H), 6.34 (dd, J
= 3.0, 1.8 Hz, 1H), 6.87 (d, J = 8.7 Hz, 2H), 6.90 (d, J = 1.2 Hz, 1H), 7.22 (d, J = 8.7 Hz, 2H),
7.45 (dd, J = 1.8, 0.9 Hz, 1H), 7.71 (d, J = 0.9 Hz, 1H); 13C NMR (75 MHz, CD3OD) δ 41.25,
108.30, 110.14, 115.18, 120.03, 125.56, 130.38, 133.53, 137.59, 142.82, 149.70, 157.74. Anal.
HPLC (Ret. time: 2.0 min., Area%: 99%). Anal. Calcd for C14H12N2O2 • 0.2H2O: C, 68.95; H,
5.13; N, 11.49; Found: C, 69.07; H, 5.09; N, 11.42.
4-(1-(2-(1H-indol-3-yl)ethyl)-1H-imidazol-5-yl)phenol (17)
The desired product 23 was collected as a yellow solid (0.23 g, 77.2%). mp: 210 - 215°C. 1H
NMR(300 MHz, CD3OD) δ 3.00 (t, J = 6.9 Hz, 2H), 4.27 (t, J = 7.2 Hz, 2H), 6.81-6.85 (m, 4H),
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6.92-6.97 (m, 1H), 7.05-7.08 (m, 1H), 7.13 (d, J = 8.7 Hz, 2H), 7.19 (d, J = 7.8 Hz, 1H), 7.30 (d,
J = 9 Hz, 1H), 7.48 (s, 1H);

13

C MNR (75 MHz, CD3OD): δ 26.64, 45.71, 110.26, 110.84,

115.19, 117.56, 118.36, 120.99, 122.45, 125.53, 126.95, 130.27, 133.30, 136.62, 137.49, 157.56.
Anal. HPLC (Ret. time: 3.7 min, Area%: 99%). Anal. Calcd for C19H17N3O • 0.3H2O: C, 73.91;
H, 5.75; N, 13.61. Found: C, 74.04; H, 5.73; N, 13.68.

Discovery and Synthesis of Pyrimidine Molecules as IspF and IspE Inhibitors

Introduction
We designed our fusion and imidazole series of lead compounds based on the fragment
based drug discovery theory. In contrast, other chemical series can also provide us with different
methods of lead molecule design which does not follow with the theory of fragment linking
(fusion series) and fragment growing (imidazole series).
In our research, coordination of lead molecules to the zinc binding site has been
demonstrated to be important. It is well known that matrix metalloprotease (MMP) inhibitors
bind to zinc in the catalytic site of MMP, such inhibition is responsible for numerous biological
activities.31 The general structure of the MMP includes a three histidine residues-bound zinc in
the conserved active site.32 A typical MMP inhibitor should contains a peptidomimetic backbone
with a “metal chelator” capable of binding to zinc31,32 (Figure 12).
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Figure 12 Typical binding model of varies MMP

In collaboration with Dr. Michael Clare at Emerald Biostructures, we initiated the design
of a new chemical series that shares a similar binding strategy with known MMP inhibitors. As a
result, the chelate structures, which contain 5 or 6 member ring systems, had been generated and
the pyrimidine series became our primary target to study (Figure 13). Hypothetically, the
pyrimidine derivatives will bind to the zinc through both the carbonyl group on the aromatic ring
and the carboxylic acid functional group. Unlike the fusion and imidazole series, no crystal
structure of pyrimidine bound to BpIspF was reported which increases the difficulty of the lead
compound design. In order to collect the preliminary data on this chemical series, we decided to
synthesize several analogs which contained the pyrimidine core as well as substituents similar to
the imidazole series, as described previously. Additionally, the combination of SPR and antimalarial data can greatly help us to determine the feasibility and affinity of this chemical series.
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Figure 13 Design of pyrimidine series as zinc-binding molecules

Synthesis of pyrimidine series
The pyrimidine core 18 was built by Michael addition of S-methyl isothiourea with
diethyl 2-(ethoxymethylene) malonate followed by cyclization. The resulting pyrimidine was
treated with a variety of amines to obtain final products (Scheme 4). Compound 19 was
synthesized by the same nucleophilic substitution with 4-iodoamine followed by a Suzuki
coupling. Additionally, sodium salts were made for all the ester products in order to increase
their solubility for SPR assay.

Scheme 4 Synthesis of pyrimidine series
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Scheme 5 Synthesis of pyrimidine compound 19

SPR, anti-bacterial, anti-malarial and herbicidal assay

In general, the compounds of the pyrimidine series exhibit limited aqueous solubility
when performing the SPR assay. In order to overcome these solubility limitations, Sriram
Jakkareju as one of our group members optimized the buffer condition for the SPR assay of
BpIspF. Two compounds (compound 19 and 24) as sodium salts were found to exhibit
reasonable log curves and showed KD values of 16 and 305 µM respectively. (Figure 14 and 15)
Additionally, Dr. Matthew Byrd at the University of Carolina at Chapel Hill offered us an
opportunity to screen pyrimidine compounds against Burkholderia pseudomallei. In this assay, a
series of pyrimidine compounds were tested, with only one, compound 24 (structure shown in
Table 3), exhibiting activity against Burkholderia pseudomallei at 1mM concentration. The
activity of compound 24 was then compared to that of Kanamycin at 300 μg/ml (Kan300), a
triazole compound (synthesized by Phumvadee Wangtrakuldee from our group), nitroxoline and
FOL955 (fragment hit).
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Figure 14 Log curve and SPR result of compound 19

Figure 15 Log curve and SPR result of compound 24

Figure 16 shows the inhibition of B. pseudomallei by each compound (at 1 mM) along
with a blank and Kanamycin as negative control, which completely inhibits the growth of the
parasite. Pyrimidine compound 24 showed similar activity to that of Kanamycin and nitroxoline,
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which are known to be effective antibiotics. Furthermore, a dose-response curve was generated
for compound 24 and decreasing activity was observed when the concentration of inhibitor was
lower than 1 mM (Figure 17).

Figure 16 Anti-bacterial activity of compound 24 (HGN-0028, showed as orange line) against
Burkholderia pseudomallei at 1mM.

The pyrimidine compounds were also tested in the anti-malarial assay against three drugresistant strains of P. falciparum (Table 3). Only two of the pyrimidine compounds (32 and 37)
showed activity against all three strains, which might be due to the solubility limitation of the
compounds. Further optimization on the structure of pyrimidine compounds is in progress.
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Figure 17 A dose-response curve of compound 24.

We also collaborated with Dr. Illarionov at the University of Hamburg in Germany to
obtain the activity of the pyrimidine compounds against IspF from Arabidopsis thaliana.
Compounds 21, 24, 29, 30, and 36 showed high micromolar activity which provided an
alternative application of the pyrimidine series as potential herbicidal agents (Table 4). Since the
MEP pathway is found in higher order plant species and considering the limitation on current
herbicidal agents, future exploration of pyrimidine series as inhibitors of plant IspF will afford
more scientific interest on our research and expand the diversity on designing MEP inhibitors.
Pyrimidine analogs as IspE inhibitors
IspE is a unique enzyme compared to IspD and IspF because it is a kinase which
catalyzes the ATP- and Mg2+ dependent phosphorylation of the tertiary alcohol of CDP-ME to
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give 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate (CDP-ME2P).33 Computational
modeling of E. coli IspE with CDP-ME and ATP-analog adenosine-5’-(γ-imino) triphosphate as
a complex (PDB: 1OJ4) provides structural information of the active site. With assistance of
MOLOC docking software, Dr. Diederich reported the result of compound 38 in the active site of
Escherichia coli IspE.33-36 Generally, the cytosine moiety of the inhibitor forms a sandwich type
structure including Phe185 and Tyr25 (π-π stacking) with additional hydrogen binding
interactions to the backbone and the side-chain of His26. Additionally, the sulfonamide moiety
creates important hydrogen bonding to Lys10, Asn12 and Asp141 (Figure 18). Guided by this
docking result, docking was performed on the Sybyl software for compound 38 with two
compounds from the pyrimidine series in order to investigate their possible binding pattern
within the active site. Fortunately, the same sandwich type of structure was observed for the
cytosine moiety of the sample inhibitor although the sulfonamide did not make any hydrogen
bonding with the amino acid residues, which might result from the different algorithm used for
Sybyl vs MOLOC (Figure 19). Interestingly, our pyrimidine compounds 24 and 33 formed a
similar π-π stacking interaction with Phe185 and Tyr25. Additionally, hydrogen bonding was
observed for the pyrimidine core to His26 (Figure 20 and 21). Moreover, the results from the
University of Hamburg show micromolar activity of pyrimidine series against Solanum
lycopersicum IspE (Table 5).
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Table 3 Anti-malarial assay of pyrimidine compounds against three drug-resistant strains of P.
falciparum

D6

C235

W2

D6

C235

W2

(µM)

(μM)

(μM)

(µM)

(μM)

(μM)

19

>40

>40

>40

29

>40

>40

>40

20

>40

>40

>40

30

>40

>40

>40

21

>40

>40

>40

31

29.29

>40

>40

22

>40

>40

>40

32

17.45

27.58

17.59

23

>40

>40

>40

33

N.A.

N.A.

N.A.

24

>40

>40

>40

34

34.52

>40

>40

25

>40

>40

>40

35

N.A.

N.A.

N.A.

26

>40

>40

>40

36

>40

19.68

16

27

>40

>40

>40

37

26.95

32.98

13.19

28

>40

>40

>40

No.

R

No.

R
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Table 4 Activities of pyrimidine compounds against AtIspF

No.

R

AtIspF
(µM)

No,

R

AtIspF
(µM)

19

>1000

29

691 +/- 105

20

>1000

30

580 +/- 48

21

629 +/- 46

31

>1000

22

>1000

32

>1000

23

>1000

33

>1000

24

460 +/- 43

34

>1000

25

>1000

35

>1000

26

>1000

36

872 +/- 65

27

>1000

37

>1000

28

>1000
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Figure 18 Reported docking result of compound 38 in the active site of E.coli IspE36.

Figure 19 Docking result of compound 38 in the active site of E. coli IspE (PDB: 1OJ4, performed by
SYBYL-X 2.0)
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Figure 20 Docking result of 24 in the active site of E. coil IspE

Figure 21 Docking result of 33 in the active site of E. coil IspE
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With no literature precedent concerning the binding of pyrimidine compounds to IspE, it
is possible to apply docking software for this series generate a hypothetical binging pattern and
re-evaluate our future direction. Docking results (Figure 19 and 20) showed the pyrimidine core
preferably also formed a sandwich type of structure with Phe185 and Tyr25. Either the nitrogen
on the pyrimidine ring or the oxygen of carbonyl group interacted with His26 through hydrogen
bonding. The difference in the orientation of the ester group was due to the energy minimization
performed by SYBYL. Despite the lack of a co-crystalline structure of pyrimidine compounds
bond to the active site of E. coli IspE, computational modeling can still afford us a general idea
of the potential binding interactions and provide a theoretical support for the affinity of
pyrimidine compounds against SiIspF.

Conclusions
Pyrimidine compounds were successfully generated based on the MMP inhibitors and the
results of anti-bacterial, anti-malarial, herbicidal assay were collected. Docking analysis of 29
and 33 provided a hypothesis of pyrimidine compound binding to the active site of EcIspE.
Further optimization on the structure of pyrimidine compounds and the docking analysis are in
progress.
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Table 5 Activities of pyrimidine compounds against SlIspF

No.

R

SlIspE
(µM)

No,

R

SlIspE
(µM)

19

>1000

30

>1000

20

>1000

31

338 +/- 86

21

670 +/- 99

32

>1000

22

>1000

33

619 +/- 162

23

>1000

34

258 +/- 24

24

419 +/- 31

35

468 +/- 30

25

750 +/- 144

36

>1000

26

>1000

37

225 +/- 24

27

>1000

38

>1000

28

>1000
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Experimental section
General method for preparing pyramiding compounds 19-37
A mixture of ethyl 2-(methylthio)-6-oxo-1, 6-dihydropyrimidine-5-carboxylate and
various amine (1 eq) was heated under neat condition for 15 h. After cooling the reaction
mixture to room temperature, the solid residue was washed with 5 ml of ethanol for 15 min and
collected via vacuum filtration.
Surface plasmon resonance
SPR binding experiments were performed on a Reichert SR7000DC (with a SR7500DC
upgrade) using a high density 500,000 Da carboxymethyl dextran SR7000 gold sensor slide. IspF
was coupled to the sensor slide using amine coupling chemistry. Initially, the surface was
activated

by

injecting

a

dimethylaminopropyl)carbodiimide

mixture

of

hydrochloride)

75

mg/ml
and

11.5

EDC
mg/ml

(N-Ethyl-N′-(3NHS

(N-

hydroxysuccinimide) for 7 min using a 50 μl/min flow rate. IspF, diluted in 10 mM 5.0 pH
sodium acetate buffer at a final concentration of 120 μg/ml, was injected over the surface for 10
min at 30 μl/min. Excess succinamide ester groups were quenched with an injection of 1M
ethanolamine for 6 min with a 50 μl/min flow rate. A total of 4000-7500 μRIU (Refractive index
units) of IspF were coated on the slide. Binding experiments were conducted at 20°C in 50 mM
sodium phosphate pH 7.4/150 mM NaCl/4.76% DMSO at 50 μl/ min. Initially, compounds were
dissolved in DMSO at 20 mM and were diluted (20-fold) into 50 mM sodium phosphate pH
7.4/150 mM NaCl, to produce a 1 mM compound sample with 4.76% DMSO, thereby
minimizing buffer mismatch. A concentration series of compound from 1 mM to 0.8 μM (diluted
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using running buffer) was generated and injected over the IspF surface. Blank (Buffer-only)
injections were included between each compound injection, allowing for double subtraction
(reference cell and buffer) during data processing. Data processing and analysis was performed
using Scrubber (BioLogic Software).

Ethyl 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (18)
To a stirred solution of diethyl 2-(ethoxymethylene)malonate (5.0 g, 0.023 mol) and Smethylisothiourea hemisulfate salt (1.5 eq) in H2O (40 mL) was added KOH solution (3.25 g
KOH pellets in 10 ml H2O) dropwise in an ice-water bath. The reaction was first stirred for 1h at
0oC and then warmed up to room temperature overnight. The initial precipitate was removed by
filtration and the pH of the filtrate was adjusted to 3 with 2 M HCl solution. The filtrate was
stirred for 1h and the resulting white precipitate was collected by filtration and recrystallized
from toluene (10 mL)to yield ethyl 2-(methylthio)-6-oxo-1,6-dihydropyrimidine-5-carboxylate 1
(2.56 g, 52% yield). 1H NMR (300 MHz, DMSO-D6): δ 1.25 (t, J = 7.2 Hz, 3H); 2.53 (s, 3H),
4.20 (q, J = 6.9 Hz, 2H); 8.44 (s, 1H-pyrimidine); Anal. HPLC: Ret. Time: 2.5 min, Area%:
92%; Anal. Calcd for C8H10N2O3S • 0.15H2O: C: 44.29, H: 4.79, N: 12.91; Found: C: 44.62, H:
4.57, N: 12.42.
Ethyl 6-oxo-2-((4-(pyridin-4-yl)phenyl)amino)-1,6-dihydropyrimidine-5-carboxylate (19)
A mixture of ethyl 2-(methylthio)-6-oxo-1, 6-dihydropyrimidine-5-carboxylate (361 mg, 1.685
mmol) and 4-iodoaniline (2 eq) was heated in ethanol under reflux for 72 h. After cooling the
reaction mixture to room temperature, the solid residue was washed with ethanol and collected
via vacuum filtration. After 1H NMR confirmed the desired product, it was taken directly to the
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next step without further purification. Ethyl 4-hydroxy-2-((4-iodophenyl)amino)pyrimidine-5carboxylate (547 mg, 1.42 mmol), Na2CO3 (2 eq), and pyridin-4-ylboronic acid (1.2 eq) were
dissolved in water/dioxane (1:2 mixture) and bubbled with N2 for 15 min. Then the Pd catalyst
(0.1 eq) was added and the reaction was heated under 100 oC overnight. After the product
formation from TLC result, the reaction mixture was cooled down to rt and diluted with 16 ml of
water. The solution was then extracted with EtOAc (50 ml * 3). The crude product was filtered
and air dried. Column purification first time (5% MeOH in DCM with 1% acetic acid to 20%
MeOH in DCM with 1% acetic acid) and second time (10% MeOH in EtOAc with 1% acetic
acid to 20% MeOH in EtOAc with 1% acetic acid) by dry loading method yield desired product
(196 mg, 41% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.25 (t, J = 7.2 Hz, 3H), 4.11 (q, J =
7.2 Hz, 2H), 7.63-7.69 (m, 4H), 8.02 (d, J = 8.7 Hz, 2H), 8.41 (s, 1H-pyrimidine), 8.53 (d, J =
6.3 Hz, 2H), 9.08 (s, 1H-NH).

13

C NMR (DMSO-D6, 75 MHz): δ 14.30, 21.61, 58.99, 119.67,

120.32, 126.79, 129.51, 141.69, 146.59, 150.04, 159.47, 161.18, 165.62, 172.89. MS (ESI, QIT)
m/z: [M + H]+ Calcd for C18H16N4O3 337.35, Found 337.20.

Ethyl 6-oxo-2-(((tetrahydrofuran-2-yl)methyl)amino)-1,6-dihydropyrimidine-5-carboxylate
(20) (176 mg, 47% yield). 1H NMR (DMSO-D6, 500 MHz): δ 1.22 (t, J = 4.2 Hz, 3H), 1.51-1.55
(m, 1H), 1.81-1.94(m, 3H), 3.34 (br, 1H), 3.47 (br, 1H), 3.65 (q, J = 4.2 Hz, 1H), 3.77-3.79 (m,
1H), 3.94-3.96 (m, 1H), 4.14 (q, J = 4.2 Hz, 2H), 8.37 (s, 1H-pyrimidine). 13C NMR (DMSO-D6,
75 MHz): δ 14.25, 25.20, 28.20, 59.19, 67.28, 76.55, 104.14, 157.20, 158.71, 162.55, 164.14.
MS (ESI, QIT) m/z: [M + H]+ Calcd for C12H17N3O4 268.29, Found 268.00.
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Ethyl 2-([1,1'-biphenyl]-4-ylamino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (21)
(59 mg, 37% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.26 (t, J = 6.9 Hz, 3H), 4.19 (q, J = 7.2
Hz, 2H), 7.33-7.36 (m, 1H), 7.43-7.48 (m, 2H), 7.65-7.72 (m, 6H), 8.51 (s, 1H-pyrimidine). MS
(ESI, QIT) m/z: [M + H]+ Calcd for C19H17N3O3 336.37, Found 336.10.

Ethyl 6-oxo-2-((4-(piperidin-1-yl)phenyl)amino)-1,6-dihydropyrimidine-5-carboxylate (22)
(88mg, 55% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 1.51-1.65 (m,
6H), 3.07-3.10 (m, 4H), 4.16 (q, J = 7.2 Hz, 2H), 6.89 (d, J = 9 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H),
8.41 (s, 1H-pyrimidine), 9.30 (br, 1H-NH). MS (ESI, QIT) m/z: [M + H]+ Calcd for C18H22N4O3
343.40, Found 343.20.
Ethyl 2-((4-morpholinophenyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (23)
(294 mg, 59% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 3.05-3.09 (m,
4H), 3.72-3.75 (m, 4H), 4.15 (q, J = 7.2 Hz, 2H), 6.93 (d, J = 9.3 Hz, 2H), 7.40 (d, J = 9.0 Hz,
2H), 8.41 (s, 1H-pyrimidine), 9.81 (s, 1H-NH), 11.18 (br, 1H-OH). MS (ESI, QIT) m/z: [M +
H]+ Calcd for C17H20N4O4 345.37, Found 345.20.

Ethyl 2-((4-chlorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (24)
(126 mg, 25% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 2.81 (t, J = 7.2
Hz, 2H), 3.55 (br, 2H), 4.13 (q, J = 7.2 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz,
2H), 7.61 (br, 1H-NH), 8.36 (s, 1H-pyrimidine). 13C NMR (DMSO-D6, 75 MHz): δ 14.25, 59.20,
104.03, 128.21, 130.64, 130.85, 137.83, 157.07, 158.90, 162.58, 164.18. MS (ESI, QIT) m/z: [M
+ H]+ Calcd for C15H16ClN3O3 322.77, Found 322.10.
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Ethyl 2-([1,1'-biphenyl]-3-ylamino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (25)
(246 mg, 49% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.25 (t, J = 6.9 Hz, 3H), 4.18 (q, J =
7.2 Hz, 2H), 7.40-7.51 (m, 5H), 7.58-7.67 (m, 3H), 7.89 (s, 1H), 8.50 (s, 1H-pyrimidine), 10.24
(s, 1H-NH), 11.46 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for C19H17N3O3 336.37,
Found 336.10.

Ethyl 2-((1H-indazol-6-yl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (26)
(227 mg, 45% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.26 (t, J = 7.2 Hz, 3H), 4.19 (q, J =
7.2 Hz, 2H), 7.14 (d, J = 8.4 Hz, 1H), 7.70 (d, J = 4.2 Hz, 1H), 8.00 (s, 1H), 8.11 (s, 1H), 8.50 (s,
1H-pyrimidine), 10.52 (s, 1H-NH), 11.50 (s, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for
C14H13N5O3 300.29, Found 300.10.

2-(4-((5-(ethoxycarbonyl)-6-oxo-1,6-dihydropyrimidin-2-yl)amino)phenyl)acetic acid (27)
(235 mg, 47% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 3.54 (s, 2H),
4.17 (q, J = 7.2 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 8.45 (s, 1Hpyrimidine), 10.21 (br, 1H-NH). MS (ESI, QIT) m/z: [M + H]+ Calcd for C15H15N3O5 318.30,
Found 318.10.

Ethyl 2-((1H-indazol-5-yl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (28)
(74 mg, 52% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.24 (t, J = 7.2 Hz, 3H), 4.17 (q, J = 7.2
Hz, 2H), 7.39 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 9 Hz, 1H), 8.00 (s, 1H), 8.06 (s, 1H), 8.45 (s, 1H-
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pyrimidine), 9.47 (br, 1H-NH), 11.30 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for
C14H13N5O3 300.29, Found 300.10.

Ethyl 2-((furan-2-ylmethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (29)
(200 mg, 54% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 4.13 (q, J =
7.2 Hz, 2H), 4.55 (d, J = 5.4 Hz, 2H), 6.32 (d, J = 3.3 Hz, 1H), 6.40 (d, J = 4.4 Hz, 1H), 7.60 (s,
1H), 7.73 (br, 1H-NH), 8.38 (s, 1H-pyrimidine), 11.24 (br, 1H-OH).

13

C NMR (DMSO-D6, 75

MHz): δ 14.24, 59.27, 104.65, 107.41, 110.50, 142.47, 151.13, 156.85, 158.71, 162.42, 164.07.
MS (ESI, QIT) m/z: [M + H]+ Calcd for C12H13N3O4 264.26, Found 264.00.

Ethyl 2-((4-fluorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (30)
1

H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 2.81 (t, J = 7.2 Hz, 2H), 3.55 (br,

2H), 4.12 (q, J = 7.2 Hz, 2H), 7.09-7.14 (m, 2H), 7.25-7.30 (m, 2H), 7.53 (br, 1H-NH), 8.36 (s,
1H-pyrimidine).

13

C NMR (DMSO-D6, 75 MHz): δ 14.24, 59.20, 103.88, 114.82, 115.10,

130.47, 130.58, 134.90, 134.94, 157.16, 159.25, 160.63, 162.46, 162.61, 164.23, 213.67. MS
(ESI, QIT) m/z: [M + H]+ Calcd for C15H16FN3O3 306.31, Found 306.10.

Ethyl 2-((4-fluorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (31)
(64 mg, 47% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2
Hz, 2H), 4.53 (d, J = 6.0 Hz, 2H), 7.13-7.19 (m, 2H), 7.33-7.53 (m, 2H), 7.51 (br, 1H-NH), 8.37
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(s, 1H-pyrimidine), 11.20 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for C14H14FN3O3
292.28, Found 292.00.

Ethyl 2-((3-fluorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (32)
(62 mg, 43% yield). 1H NMR (DMSO-D6, 500 MHz): δ 1.23 (t, J = 4.2 Hz, 3H), 2.85 (t, J = 4.2
Hz, 2H), 3.60 (br, 2H), 4.13 (q, J = 4.2 Hz, 2H), 7.03-7.12 (m, 3H), 7.33-7.37 (m, 1H), 8.38 (s,
1H-pyrimidine), 11.07 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for C15H16FN3O3
306.31, Found 306.10.

Ethyl 2-((2-chlorophenethyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (33)
1

H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 2.95 (t, J = 7.2 Hz, 2H), 3.59 (br,

2H), 4.13 (q, J = 7.2 Hz, 2H), 7.25-7.60 (m, 4H), 7.60 (br, 1H-NH), 8.38 (s, 1H-pyrimidine). MS
(ESI, QIT) m/z: [M + H]+ Calcd for C15H16ClN3O3 322.77, Found 322.10.

Ethyl 2-((2-chlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (34)
(195 mg, 45% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J =
7.2 Hz, 2H), 4.63 (d, J = 5.1 Hz, 2H), 7.31-7.35 (m, 3H), 7.45-7.48 (m, 1H), 7.92 (br, 1H-NH),
8.35 (s, 1H-pyrimidine). 13C NMR (DMSO-D6, 75 MHz): δ 14.23, 41.57, 59.26, 127.27, 128.67,
128.87, 129.19, 130.10, 131.96, 135.49, 157.24, 159.01, 162.40, 164.11. MS (ESI, QIT) m/z: [M
+ H]+ Calcd for C14H14ClN3O3 308.74, Found 308.00.
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Ethyl 2-((3-chlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (35)
(77 mg, 53% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.22 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2
Hz, 2H), 4.56 (d, J = 6.0 Hz, 2H), 7.26-7.40 (m, 4H), 8.01 (br, 1H-NH), 8.36 (s, 1H-pyrimidine).
MS (ESI, QIT) m/z: [M + H]+ Calcd for C14H14ClN3O3 308.74, Found 308.00.

Ethyl 2-((4-chlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (36)
1

H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2 Hz, 2H), 4.54 (d, J =

5.7 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 7.40 (d, J = 8.1 Hz, 2H), 7.78 (br, 1H-NH), 8.35 (s, 1Hpyrimidine), 11.35 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for C14H14ClN3O3 308.74,
Found 308.00.

Ethyl 2-((3,4-dichlorobenzyl)amino)-6-oxo-1,6-dihydropyrimidine-5-carboxylate (37)
(80 mg, 50% yield). 1H NMR (DMSO-D6, 300 MHz): δ 1.21 (t, J = 7.2 Hz, 3H), 4.13 (q, J = 7.2
Hz, 2H), 4.54 (d, J = 6.0 Hz, 2H), 7.30 (dd, J = 8.1, 1.8 Hz, 1H), 7.57-7.61 (m, 2H), 7.61 (br,
1H-NH), 8.35 (s, 1H-pyrimidine), 11.32 (br, 1H-OH). MS (ESI, QIT) m/z: [M + H]+ Calcd for
C14H13Cl2N3O3 343.18, Found 342.00.

CHAPTER 2
Background
Phosphodiesterase 4(PDE4) family of enzymes and their structural information related to
inhibitors
cAMP is a second messenger in cells acts as a regulator for the action of neurotransmitter
signals.2 It is responsible for inflammatory responses as well as cell growth, differentiation and
survival.37 As a cyclic nucleotide, cAMP is highly regulated by certain proteins for local
synthesis and degradation.2 Phosphodiesterases (PDEs), one type of these proteins, is a super
family of cyclic nucleotides which cleaves the phosphodiester bond in cAMP and causes the
hydrolysis of cAMP, respectively. The importance of PDEs is highlighted by their sequence
conservation among the catalytic domains of the eleven family members (PDE1-11) while they
can still be distinguished by a unique regulatory domain.2 Table 6 shows the location and
function of each PDE family members.38
PDE4 is known to be the primary cAMP-metablizing enzyme. Four genes represent
different isoforms of PDE4 (PDE4A, B, C and D) and they all contain upstream conserved
region 1 (UCR1) and 2 (UCR 2). UCR 2 is known to be responsible for the regulation of cAMP
hydrolysis as well as binding affinity for Rolipram, one known PDE4 inhibitor. 2 Besides the
UCR 1 and 2, PDE4 family can still be differentiated by their N-terminal sequences. Moreover,
three basic isoforms can be categorized from all gene types of PDE4 (A, B, C and D) which
include

the

long

isoforms,

short

isoforms

and

super-short

isoforms.2
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Table 6 PDE families, inhibitors and functions

Family
(Number of
genes in

Specificities; Tissue Distribution; and Function

Inhibitors

Ca2+/calmodulin-stimulated; found in heart, brain, lung, smooth muscle; PDE1A

Nimodipine,

regulates smooth muscle contraction and plays role in sperm function. PDE1B is

IC86340, IC224,

responsible for dopaminergic signaling and immune cell activation and survival.

IC295, dioclein

family)

PDE1
(3)

PDE1C is involved in vascular smooth muscle cell proliferation, sperm function, and
neuronal signaling.

EHNA, BAY-60–
PDE2

cGMP-stimulated; found in adrenal gland, heart, lung, liver, platelets, endothelial

7750, PDP,

(1)

cells; PDE2 mediates the interaction of cGMP and cAMP pathways regulating

IC933, oxindole,

aldosterone secretion from the adrenal gland, cAMP and PKA phosphorylation of

ND7001

Ca2+ channels in the heart, cGMP in the neurons, long term memory, and barrier
function of endothelial cells under inflammatory conditions.

cAMP-selective, cGMP-inhibited; found in heart, smooth muscle, lung, liver, platelets,
PDE3

adipocytes, immunocytes; PDE3A regulates cardiac contractility, platelet aggregation,

Cilostamide,

(2)

vascular smooth muscle contraction oocyte maturation, and regulation of renin release.

milrinone,

PDE3B mediates insulin signaling, especially antilipolytic effects and regulates cell

siguazodan,

cycle/proliferation and mediates the inhibitory effects of leptin and other signals on
insulin secretion and renin release.

cilostazol

cAMP-specific, cGMP-insensitive; found in brain, Sertolli cells, kidney, liver, heart,
PDE4

smooth muscle, lung, endothelial cells, immunocytes; PDE4 is expressed in at least

Rolipram,

(4)

one of its forms in most cells. The isoforms play a role in a wide array of processes,

roflumilast,

including brain function, momocyte and macrophage activation, neutrophilo

cilomast, NCS

infiltration, vascular smooth muscle proliferation, fertility, vasodilation, and cardiac
contractility.

613
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Table 6 Continued

cGMP-specific; found in Lung, platelets, smooth muscle, heart, endothelial cells,
PDE5

brain; PDE5 is well-documented as a regulator of vascular smooth muscle contraction,

Zaprinast,

(1)

especially in the penis and lung. It is involved in NO-cGMP signaling in platelets to

DMPPO,

control aggregation and may also play a role in regulation of cGMP signaling in the

sildenafil tadalafil,

brain.
vardenafil

cGMP-specific; found in Photoreceptors, pineal gland, lung; PDE6 is evolved in single
PDE6

transduction of the photoresponse in the eye and regulates melatonin release from the

Zaprinast,

(3)

pineal gland.

DMPPO,
sildenafil,
vardenafil

cAMP-specific, high-affinity rolipram-insensitive; found in skeletal muscle, heart,
PDE7

kidney, brain, pancreas, T lymphocytes; PDE7 is implicated to play a role in T-cell

BRL 50481,

(2)

activation and activation of other inflammatory cells.

IC242, ASB16165

cAMP-selective, rolipram-insensitive; found in testes, eye, liver, skeletal muscle,
PDE8

heart, kidney, ovary, brain, T lymphocytes, thyroid; PDE8 plays a role in T cell

(2)

activation, sperm or leydic cell function.

PF-04957325

cGMP-specific; found in kidney, liver, lung, brain; PDE9 has an unknown function,
PDE9

but may play a role in regulating NO-cGMP signaling in the brain.

BAY-73–6691,
PF-04447943

(1)

cGMP-sensitive, cAMP-selective; found in testes, brain, thyroid; PDE10A regulates
PDE10

cGMP in the brain and plays a role in learning and memory.

Papaverine, TP10, MP-10

(1)

PDE 11

cGMP-sensitive, dual specificity; found in skeletal muscle, prostate, pituitary gland,

(1)

liver, heart; PDE11 is involved in sperm development and function.

None selective
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They all maintain the catalytic domain within the gene sequence but with major
differences being the lack of UCR 1 or the inclusion of a truncated UCR 2.2 Although no
evidence exists demonstrating the preference of PDE4 inhibitor binding towards UCR 1 or UCR
2, a wide body of research has suggested that UCR 2 is highly responsible for the affinity of
rolipram and related analogs compared to those isoforms only containing the catalytic domain.
Recently, a study by Burgin et al. confirmed that the PDE4 inhibitors will interact with both
UCR 2 and the active site of protein.2

Previous studies on the PDE4 inhibitors
Since cAMP regulates inflammatory responses and physiologically affects the central
nervous system (CNS), suppression of PDE4 will yield non-metabolized cAMP, with the
elevated level of cAMP resulting in a variety of therapeutic benefits. To be more specific, PDE4
is a potential target mostly for the research on CNS disorders, cognitive disorders and strokes.
Inhibition of PDE4 may also result in anti-depressant, antipsychotic and cognition enhancement
properties.39 Although a large body of research has been conducted concerning the discovering
PDE4 inhibitors, most of studies are still in the early investigation stage due to the side effects
observed for current inhibitors such as emesis and diarrhea.40 Examples of known PDE4
inhibitors are shown in Figure 22. The observed side effects result from the fact that competitive
PDE4 inhibitors will not only alter cAMP concentration but will also alter the normal
physiological level of cAMP, which will disorder the temporal and spatial signals of cAMP in
cells.2
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Recent research has been focused on the development of partial PDE4D inhibitors which
are also known as allosteric modulators since they are not directly bound to the active site of
PDE4D. Burgin et al. have generated sufficient SAR data to indicate the pharmacophore that
correlates to the allosteric effect of inhibitors.2 Generally, the desired PDE4D inhibitors contain a
planar aromatic core which provides hydrogen bond accepting capability, a linker and two other
aromatic functional groups to help UCR 2 maintain position across the active site. A decrease in
the interaction of the hydrogen bond acceptor on the core and a single aromatic system in the
core can potentially increase the possibility of partial inhibition. Additionally, the absence of the
linker on one of the aromatic substituents will also deteremine the partial inhibitory behavior.2
In order to evaluate the efficacy on the cognition enhancement and reduction of the
emesis side effect, a rodent cognition test and a behavioral correlate test (ketamine/xylazine)
were performed to show the allosteric PDE4 modulators do provide benefit on memory
improvement as well as prevention on emetic potential.2 Thus, it is obvious to predict that future
discovery of PDE4 partial inhibitors will greatly increase their availability as potential drug
candidates with minimum side effects.
Besides the therapeutic effect on CNS, recent study suggested that PDE4 inhibitors can
target Trypanosoma brucei, a parasite causing human African trypanosomiasis (HAT).41 Millions
of people are at risk of HAT and current treatments, including Melarsoprol and Eflornithine, still
exhibit severe side effects. Research has shown that two cAMP-specific PDEs expressed in T.
brucei, TbrPDEB1 and TbrPDEB2, are responsible for the proliferation of the parasite by both
RNAi and small molecules.41,42 Furthermore, a typical human PDE4 inhibitor, Piclamilast, was
screened and was found to have inhibition against TrbPDEB1 and B2 (IC 50 = 4.7 and 11.4 Μm
respectively) (Figure 23).
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Considering this, PDE4 inhibitors may have antibacterial activity, which provides a
correlation between our research on the synthesis of PDE4 inhibitors and our MEP pathway
inhibitors discovery.

Figure 22 Examples of PDE4 inhibitors
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Figure 23 Typical hPDE4 inhibitors showed activities against TbrPDEB1 and B2

Revised Synthesis for PDE4D Inhibitors
Introduction
Three compounds have been reported as novel PDE4D partial inhibitors (D159687,
D159404, D159153). Collaboration with Dr. Gurney at Tetra Discovery Partners LLC offered us
a chance to investigate these compounds and provided opportunity to develop new synthetic
pathways to obtain the desired products.
The original six-step synthesis of D159687 is shown in Scheme 6.43 The aldehyde is
reduced to the corresponding alcohol with NaBH4. The 3-chlorophenyl group is then introduced
by Suzuki coupling to afford the corresponding biaryl system. The alcohol is then converted into
a bromide and the second aryl group is introduced using another Suzuki reaction. The urea
functionality is introduced by reduction of the nitro group followed by urea formation. The
overall 8% yield is observed for this method.
To optimize the synthesis for this compound, we began to design a new synthetic
pathway to avoid unnecessary synthetic steps and high cost of reagents.
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Scheme 6 Six-step synthesis of D159687

Concise two-step synthesis of D15968744
Our revised synthesis started with dibromide compound (38) which was converted to
desired product (41) via two sequential Suzuki coupling reactions. One possible issue in the
process was the selectivity of coupling position. However, literature precedent and our
experimental data all proved that the first reaction occurred at the benzylic rather than the aryl
position. Initial attempt in synthesizing desired compound (41) suffered from low conversion and
quantitative side products. To further optimize the reaction conditions, a variety of Pd catalysts
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with equivalent differences were tested along with a combination of bases and solvents. (Table
7)

Scheme 7 Concise two-step synthesis of D159687 (41)

As the table shows, Pd(PPh3)4 was the best catalyst for this reaction. Generally, lower
catalyst loading increased the yield of conversion (entry 1 vs 2) with an exception (entry 15 vs
17). This observation is due to the fact that higher catalyst loading will increase the amount of
impurities (less than 2%) and the catalytic ligand (PPh3), which requires more excessive
purification effort. Among the bases applied, no significant change was found for the reaction
conversion. Moreover, reactions in anhydrous DMF exhibited the lowest conversion (resulting in
starting material recovery) while the mixture of solvent (DME/EtOH/H2O) offered promising
results.
With the first Suzuki coupling reaction optimized, we applied the conditions to the
second step with same stoichiometric conditions, altering only the reaction temperature. The
overall outcome for these two sequential reactions offered us a gram scale of product.

Table 7 Optimization of conditions for the first Suzuki coupling
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Entry

Catalyst

Eq. Cat.

Base

Solvent

1

Pd(PPh3)4

0.25

K3PO4

DME/EtOH/H2O (4:1:1)

41 (%)
54

2

Pd(PPh3)4

0.08

K3PO4

DME/EtOH/H2O (4:1:1)

72

3

Pd(PPh3)4

0.15

K2CO3

DME/EtOH/H2O (4:1:1)

41

4

Pd(PPh3)4

0.15

Na2CO3

DME/EtOH/H2O (4:1:1)

50

5

Pd(PPh3)4

0.05

Na2CO3

Dioxane/H2O (3:1)

40

6

Pd(PPh3)4

0.25

Cs2CO3

DME/EtOH/H2O (4:1:1)

59

7

Pd(PPh3)4

0.15

K3PO4

Dioxane/H2O (3:1)

62

8

Pd(PPh3)4

0.15

Cs2CO3

Dioxane/H2O (3:1)

53

9

Pd(PPh3)4

0.05

K2CO3

Dioxane/H2O (3:1)

57

10

Pd(PPh3)4

0.05

K3PO4

DMF

1

11

PdCl2(PPh3)2

0.05

Na2CO3

Dioxane/H2O (3:1)

44

12

PdCl2(PPh3)2

0.25

K3PO4

DME/EtOH/H2O (4:1:1)

62

13

PdCl2(PPh3)2

0.25

Cs2CO3

DME/EtOH/H2O (4:1:1)

56

14

PdCl2(PPh3)2

0.15

K3PO4

Dioxane/H2O (3:1)

60

15

PdCl2(PPh3)2

0.15

Cs2CO3

Dioxane/H2O (3:1)

64

16

PdCl2(PPh3)2

0.05

K3PO4

DMF

6

17

PdCl2(PPh3)2

0.05

Cs2CO3

Dioxane/H2O (3:1)

59

18

PdCl2(PPh3)2

0.05

K2CO3

Dioxane/H2O (3:1)

61

19

Pd(OAc)2/PPh3 (1:4)

0.25

K3PO4

DME/EtOH/H2O (4:1:1)

55

20

Pd(OAc)2/PPh3 (1:4)

0.25

Cs2CO3

DME/EtOH/H2O (4:1:1)

52

21

Pd(OAc)2/PPh3 (1:4)

0.15

K2CO3

DME/EtOH/H2O (4:1:1)

55

22

Pd(OAc)2/PPh3 (1:4)

0.15

K3PO4

Dioxane/H2O (3:1)

60

23

Pd(OAc)2/PPh3 (1:4)

0.15

Cs2CO3

Dioxane/H2O (3:1)

57

24

Pd(OAc)2/PPh3 (1:4)

0.05

K2CO3

Dioxane/H2O (3:1)

60

25

Pd(OAc)2/PPh3 (1:4)

0.05

K3PO4

DMF

1

26

Pd(OAc)2/PPh3 (1:4)

0.05

Na2CO3

Dioxane/H2O (3:1)

53

The synthesis of D159404 and D15915344

After successfully applying a concise two-step synthesis on D159687, we aimed at
assembling the other two PDE4D allosteric modulators, D159404 and D159153, by the same
method. The fluorine containing intermediate 43 was obtained via the aldehyde functional group
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installation on the commercial compound 42 followed by reduction with NaBH4 and bromination

with NBS. As we expected, the first Suzuki coupling reaction with the boronic ester occured at
the benzylic position of 45. The urea compound 46 underwent one more Suzuki coupling with 3chlorophenylboronic acid to yield D159404 (47) and with 3-nitrophenylboronic acid to yield
D159153 (48). Modest isolated yields were recorded as 40% and 41% respectively (Scheme 8).

Scheme 8 Synthesis of D159404 and D159153

Experimental section
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General methods
All the information regard to column purification, NMR, melting point test, analytical
HPLC data and CHN analysis were obtained by same method. HRMS was obtained from
University of Illinois on a Q-Tof mass spectrometer.

1-(4-(3-bromo-4-methoxybenzyl)phenyl)urea (40): To a mixture of bromide 38 (3.6 g, 12.86
mmol, 1.06 eq.), boronic ester 39 (3.18 g, 12.13 mmol, 1.0 eq.), Pd(PPh3)4 (1.12 g, 0.97 mmol,
0.08 eq.) and potassium phosphate (5.15g, 24.26 mmol, 2 eq.) in a mixture of DME (100 ml),
water (25 ml) and ethanol (25 ml) was bubbled N2 for 25 min and then was stirred at 65oC for 3
hr until starting material was consumed. After cooling to room temperature, the insoluble
material was removed by filtration. The organic layer was evaporated and then poured into
saturated NH4Cl (aq). The solid was collected by filtration and washed with water. Then the
solid thus obtained was dissolved in DME (100 ml). After dried over Na2SO4, filtered, solvent
was removed to give a residue (5.1 g), which was treated with DCM (50 ml). The desired
product 40 was collected (2.68 g, 66% yield) as off-white solid after filtration. mp 186-195 °C;
FT-IR cm-1 3459, 3335, 3300, 3202, 1655, 1570, 1525, 1493, 1253, 1051, 1017; 1H NMR (300
MHz, DMSO-D6) δ 3.78 (s, 2H), 3.80 (s, 3H), 5.77 (br s, 2H), 7.01 (d, J = 8.4 Hz, 1H), 7.05 (d, J
= 8.0 Hz, 2H), 7.17 (dd, J = 8.4, 2.0 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 2.0 Hz, 1H),
8.42 (br s, 1H);

13

C NMR (75 MHz, DMSO-D6) δ 39.43, 56.59, 110.85, 113.09, 118.42, 129.24,

129.40, 133.16, 134.14, 136.10, 139.08, 154.03, 156.46; Anal. HPLC (Ret time: 9.85 min,
Area%: 98.37 %); Anal. Calcd for C15H15O2BrN2: C, 53.75; H, 4.51; N, 8.36. Found: C, 53.39;
H, 4.66; N, 8.03.
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1-(4-((3'-chloro-6-methoxy-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea(41): To a mixture of 40
(1.6 g, 4.77 mmol, 1.0 eq.), 3-chlorophenyl boronic acid (1.12 g, 7.16 mmol, 1.5 eq.), palladium
catalyst (440 mg, 0.38 mmol, 0.08 eq.) and potassium phosphate (2.03 g, 9.55 mmol, 2 eq.) in a
mixture of DME (60ml), water (15 ml) and ethanol (15 ml) was bubbled N2 for 15 min and then
was stirred at 80oC for overnight until starting material 40 was consumed. After cooling to room
temperature, the insoluble material was removed by filtration. The mixture was partitioned
between EtOAc and NH4Cl (aq.). The organic layer was separated and dried over Na2SO4.
Removal of solvent gave a residue, which was purified by chromatography on silica gel (120 g)
using DCM/Acetone (11:1 to 6:1). 1.18 g of product 41 (D159687) was obtained (67% isolated
yield). mp 150-158 °C; FT-IR cm-1 3446, 3317, 3204, 2926, 1633, 1585, 1528, 1473, 1458,
1341, 1239, 1026; 1H NMR (300 MHz, DMSO-D6) δ 3.74 (s, 3H), 3.83 (s, 2H), 5.76 (br s, 2H),
7.03 (d, J = 8.1 Hz, 1H), 7.08 (d, J = 8.4 Hz, 2H), 7.15-7.20 (m, 2H), 7.28 (d, J = 8.4 Hz, 2H),
7.48-7.36 (m, 4H), 8.40 (br s, 1H).;

13

C NMR (75 MHz, DMSO-D6) δ 39.97, 56.08, 112.35,

118.40, 127.14, 128.41, 129.22, 129.31, 129.86, 130.31, 131.00, 133.06, 134.66, 138.94, 140.75,
154.72, 156.47; Anal. HPLC (Ret time: 14.87 min, Area%: 98.48%); Anal. Calcd for
C21H19O2ClN2: C, 68.76; H, 5.22; N, 7.64; Found: C, 68.50; H, 5.13; N, 7.36.

3-bromo-2-fluoro-4-methoxybenzaldehyde (43): To a solution of 2-bromo-3-fluoroanisole 42
(5 g, 24.39 mmol, 1 eq.) and DCM (12 ml) cooled by an ice-water bath was bubbled N2 for 15
min. Titanium tetrachloride (12.57 ml, 115 mmol, 4.7 eq.) and dichloromethyl methyl ether
(3.31 ml, 36.6

mmol, 1.5 eq.) were added to the solution and stirred for 2 hrs under N2,

warming to room temperature. Then the solution was slowly added to ice water (625 ml) and
extracted with DCM (2x250ml). The organic layer was washed with saturated NaHCO3 solution
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(187.5 ml), water (187.5 ml), and brine (187.5 ml), and dried with MgSO4. The solvent was
removed, and the solid titurated with hexane (37.5 ml). The solid was put under vacuum for 1
hour. After drying, product 43 was collected (4.7 g, 64% yield) as a tan solid. mp: 93-94°C; FTIR cm-1 3428, 3050, 2989, 2850, 2779, 2359, 1701, 1681, 1600, 1493, 1439, 1433, 1290, 1254,
1178, 1122, 1070, 846, 814, 745, 686, 611, 518; 1H NMR (500 MHz, CDCl3) δ 4.03 (s,3H), 6.84
(d, J = 8.5 Hz,1H), 7.88 (dd, J = 8.5, 8.0 Hz,1H), 10.24 (s, 1H); 13C NMR (75 MHz, CDCl3) δ
57.06,

99.60,

107.50,

118.83,

128.66,

160.67,

162.41,

185.48;

Anal.

Calcd

for

C8H6BrFO2•0.08H2O: C, 41.23; H, 2.60 Found: C, 40.98; H, 2.65;

(3-bromo-2-fluoro-4-methoxyphenyl) methanol (44): A solution of 3-bromo-2-fluoro-4methoxybenzaldehyde 43 (4.6 g, 19.74 mmol, 1 eq.), THF (40 ml), and water (40 ml) was cooled
to 0°C, and NaBH4 (2.24 g, 59.2 mmol, 3 eq.) was added over 8 minutes. The solution was
stirred for 3.5 hrs, warming to room temperature. Then the THF was evaporated off, and water
(90 ml) was added. The solid was extracted with EtOAc (2x180 ml), washed with water (2x180
ml) and brine (180 ml), and dried with sodium sulfate. The organic solution was filtered, and the
solvent was removed over vacuum, yielding the product 44 (3.81 g, 82% yield) as an off white
powder. mp: 82-83°C; FT-IR cm-1 3287, 2932, 2884, 1616, 1494, 1466, 1290, 1174, 1127,
1076, 1028, 941, 802, 641, 489; 1H NMR (300 MHz, CDCl3) δ 3.93 (s, 3H), 4.74 (s, 2H), 6.72
(dd, J = 8.4, 1.5 Hz, 1H), 7.34 (t, J = 8.4 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 56.64, 59.20,
99.35, 106.95, 121.25, 128.30, 156.99, 159.50; Anal. HPLC (Ret. time: 4.92 min., Area%:
100%); Anal. Calcd for C8H8BrFO2: C, 40.88; H, 3.43. Found: C, 40.88; H, 3.29.
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2-bromo-4-(bromomethyl)-3-fluoro-1-methoxybenzene (45): A solution of (3-bromo-2fluoro-4-methoxyphenyl) methanol 44 (3 g, 12.76 mmol, 1 eq.), triphenylphosphine (3.35 g,
12.76 mmol, 1 eq.), and DCM (100 ml) under nitrogen was cooled to 0°C for 5 minutes. NBS
(2.272 g, 12.76 mmol, 1 eq.) was added and the reaction stirred for 2 hours at 0°C. Then the
solution was added to water (100 ml), extracted with DCM (2x100 ml), and dried with sodium
sulfate. The solution was then filtered and the solvent concentrated by vacuum to give a red oil.
The oil was purified by chromatography on silica gel using EtOAc/hexane (0:1 to 5:95 to 10:90).
The fractions containing product were combined, and the solvent removed under vacuum to yield
the product 45 (3.1 g, 77%) as an off-white solid. mp: 114-118°C; FT-IR cm-1 3432, 2945, 1610,
1491, 1447, 1307, 1289, 1215, 1174, 1149, 1074, 810, 615, 557, 507, 471; 1H NMR (300 MHz,
CDCl3) δ 3.94 (s, 3H), 4.53 (s, , 2H), 6.70 (dd, J = 8.4, 1.5 Hz, 1H), 7.32 (t, J = 8.7 Hz, 1H); 13C
NMR (75 MHz, CDCl3) δ 25.93, 56.71, 99.75, 107.20, 118.60, 129.95, 156.40, 159.70; Anal.
HPLC (Ret. time: 14.94 min., Area%: 94.28%); Anal. Calcd for C8H7Br2FO: C, 32.25; H, 2.37.
Found: C, 32.45; H, 2.19.

1-(4-(3-bromo-2-fluoro-4-methoxybenzyl)phenyl)urea

(46):

2-bromo-4-(bromomethyl)-3-

fluoro-1-methoxybenzene 45 (1.033 g, 3.47 mmol, 1 eq.), 4-(ureido)phenylboronic acid, pinacol
ester (1 g, 3.82 mmol, 1.1 eq.), and potassium phosphate (1.472 g, 6.94 mmol, 2 eq.) were
dissolved by ethanol (7 ml), water (7 ml), and DME (28 ml). Nitrogen gas was bubbled through
the solution for 25 minutes, and then tetrakis (triphenylphosphine)palladium(0) (194 mg, .168
mmol, .05 eq.) was added. The solution was stirred under nitrogen gas at 60°C for 3.5 hours
until starting material was consumed. The insoluble material was removed by filtration, and the
organic layer removed by vacuum. The solution was poured into saturated NH4Cl (45 ml),
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filtered, and washed with water. The solid was collected and dried overnight. The solid was
stirred in DCM (40 ml) for 30 minutes, filtered, and the off-white solid collected as the product
46 (799.1 mg, 65%). mp: 198-201°C; FT-IR cm-1 3472, 3297, 2353, 2341, 1653, 1589, 1546,
1490, 1440, 1412, 1348, 1270, 1251, 1076, 816, 780; 1H NMR(300 MHz, DMSO-D6) δ 3.84 (s,
5H), 5.78 (br s, 2H), 6.90 (dd, J = 8.7, 1.5 Hz 1H), 7.03 (d, J = 8.4 Hz, 2H), 7.22-7.31 (m, 3H),
8.45 (s, 1H, NH);

13

C MNR (75 MHz, DMSO-D6) δ 33.75, 57.09, 108.47, 118.30, 122.15,

129.03, 130.40, 130.48, 132.64, 139.23, 155.87, 156.39, 156.44; Anal. HPLC (Ret. time: 10.28
min,

Area%: 96.73%); Anal. Calcd for C15H14BrFN2O2•0.02H2O: C, 51.01; H, 4.00; N, 7.93.

Found: C, 50.96; H, 4.00; N, 7.92.

1-(4-((3'-chloro-2-fluoro-6-methoxy-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea

6

(47): 1-(4-(3-

bromo-2-fluoro-4-methoxybenzyl)phenyl)urea 46 (760 mg, 2.152 mmol,1 eq.), 3-chlorophenyl
boronic acid (505 mg, 3.23 mmol, 1.5 eq.), and potassium phosphate (914 mg, 4.30 mmol, 2 eq.)
were dissolved by ethanol (10 ml), water (10 ml), and DME (40 ml). N 2 was bubbled through
the solution for 20 minutes, tetrakis(triphenylphosphine) palladium(0) (199 mg, .172 mmol, .08
eq.) was added, N2 bubbled for another 5 minutes, and then the solution was stirred under N2 at
80°C for 17 hours until the starting material was consumed. The solution was cooled to room
temperature, and the insoluble material was removed by filtration. The mixture was partitioned
between EtOAc(120 ml) and sat. NH4Cl (aq.) (120 ml). The organic layer was separated, dried
over Na2SO4, and the solvent removed to give oil. The oil was purified by chromatography on
silica gel (10.16 g) using DCM/Acetone (11:1 to 1:9), the fractions containing product were
combined and the solvent removed by vacuum. Ether (5.5 ml) was added to the solid, stirred for
2 hours, and filtered, collecting the off-white solid as product 47 (353 mg, 41% yield). mp: 184-

74

188°C; FT-IR cm-1 3510, 3316, 2923, 2862, 1654, 1589, 1536, 1475, 1341, 1278, 1165, 1091,
1071, 742, 692; 1H NMR(300 MHz, DMSO-D6) δ 3.72 (s, 3H), 3.83 (s, 2H), 5.77 (br s, 2H), 6.92
(d, J = 7.8 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 7.23-7.31 (m, 4H), 7.36 (s, 1H), 7.40-7.48 (m, 2H),
8.42 (br s, 1H); 13C NMR (75 MHz, DMSO-D6) δ 31.14, 56.52, 107.87, 116.92, 118.42, 121.09,
121.33, 127.85, 129.09, 129.72, 130.25, 130.53, 131.00, 131.10, 133.05, 134.08, 139.11, 156.30;
Anal. HPLC (Ret. time: 16.22 min., Area%: 95.98%); Anal. Calcd for C21H18ClFN2O2: C, 65.54;
H, 4.71; N, 7.28. Found: C, 65.33; H, 4.66; N, 7.21.

1-(4-((2-fluoro-6-methoxy-3'-nitro-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea

(48):

1-(4-(3-

bromo-2-fluoro-4-methoxybenzyl)phenyl)urea 46 (500 mg, 1.416 mmol, 1 eq.), (3nitrophenyl)boronic acid (354 mg, 2.124 mmol, 1.5 eq.), and potassium phosphate (601 mg,
2.830 mmol, 2 eq.) were dissolved by ethanol (6 ml), water (6 ml), and DME (24 ml). N 2 was
bubbled through the solution for 20 minutes, tetrakis(triphenylphosphine) palladium(0) (131 mg,
0.113 mmol, 0.08 eq.) was added, N2 bubbled for another 5 minutes, and then the solution was
stirred under N2 at 80°C for 17 hours until the starting material was consumed. The solution was
cooled to room temperature, and the insoluble material was removed by filtration. The mixture
was partitioned between EtOAc (80 ml) and sat. NH4Cl (aq.) (80 ml). The organic layer was
separated, dried over Na2SO4, and the solvent removed.

The solid was purified by

chromatography on silica gel (20 g) using DCM/Acetone (9:1 to 1:9) follow by 20% MeOH in
DCM to wash through the column, the fractions containing product were combined and the
solvent removed by vacuum. The result solid was triturated with 5 ml ether and filtered to yield
desired product 48 (218mg, 39% yield) as a pale yellow solid mp: 209-211°C; FT-IR cm-1 3458,
3302, 1647, 1592, 1523, 1351, 1272, 1093, 787, 668; 1H NMR (300 MHz, DMSO-D6) δ 3.74 (s,
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3H), 3.86 (s, 2H), 5.77 (br s, 2H), 6.97 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 7.30 (d, J =

8.4 Hz, 3H), 7.73 (t, J = 7.8 Hz, 1H), 7.81 (dd, J = 7.5, 1.2 Hz, 1H), 8.16 (s, 1H), 8.21-8.25 (m,
1H ), 8.43 (br s, 1H);

13

C NMR (75 MHz, DMSO-D6) δ 33.66, 56.62, 108.02, 115.80, 118.45,

121.33, 122.90, 125.46, 129.11, 130.01, 131.60, 133.00, 133.56, 137.81, 139.14, 148.03, 156.07,
156.45, 159.30; Anal. HPLC (Ret. time: 13.55 min., Area%: 95.43%); Anal. Calcd for
C21H18FN3O4: C, 63.79; H, 4.59; N, 10.63. Found: C, 63.49; H, 4.49; N, 10.26. HRMS (ESI+)
calcd for C21H19FN3O4+ [M+H]+: 396.1360, found: 396.1366.
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Synthesis of Atropisomeric PDE4D Inhibitors
Introduction
Atropisomerism is a term referring to stereoisomerism of a chiral molecule, and results
from hindered rotation around a single bond (Figure 24).45 G. H. Christie and J. Kenner
reported the first example of an atropisomer in 1922 which related to a single enantiomer of
6,6’-dinitro-2,2’-diphenic acid separated by diastereoselective crystallization. Multiple drug
related molecules and natural products possess atropisomerism, which provides them
significant biological properties including pharmacodynamics and toxicity. Several examples of
drugs and candidates are shown in Figure 25.

Figure 24 Comparison of traditional enantiomer with atropisomer
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Figure 25 Examples of atropisomers as drug-like molecules

The racemization of atropisomers depends upon the intramolecular dynamic processes
that only involved bond rotation, compared to chiral compounds based on a seterogenic center
which racemize through bond breaking and forming processes. To further understand
atropisomers, the relationship between rotation rate and steric hindrance needs to be well
investigated. Atropisomers can have a slow rate of interconvertion, with half-lives greater than
1000s due to steric hindrance. This allows for the separation of such compounds under certain
circumstances. The steric hindrance results from structural differences (Figure 26) with
increasing rotation energy and half-time.46 Finally, the classification of rotation half-life
correlated to atropisomers is illustrated in Figure 27.46
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Figure 26 The effect of functional groups on rotation energy barrier and rotation T ½

Figure 27 Classification of atropisomers
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Figure 28 Typical rotation energy barrier of various biaryl system47

Design and synthesis of atropisomeric PDE4D partial inhibitors
After the optimized synthetic method had been developed for the PDE4 partial
inhibitors, an additional study on their biaryl structure determined they possess atropisomerism
because of their axial rotation ability. Despite the fact that no actual kinetic and thermodynamic
calculations can be performed with our limited resources, a preliminary study of atropisomeric
PDE4D partial inhibitors began with the synthesis of several analogs of the original chemical
series, which have either halogen atoms or methoxy group installed on the biaryl system. The
strategy behind the inhibitor design comes from a literature report suggesting energy barriers
for halogen or other functional groups substituted on biaryl molecules (Figure 28).47 The
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combination of rotational energy along with classification of atropisomers from Figure 26, 27,
and 28 indicated that bigger substituents such as halogen or methoxy groups could potentially
provide atropisomerism to our PDE4D partial inhibitors. Moreover, the introduction of
atropisomerism into PDE4D partial inhibitors could result in different mechanism against
enzymes, which will add interesting therapeutic effects on the molecules.
The synthesis of potential atropisomeric PDE4 partial inhibitors followed the same
procedure as the synthesis of D159404 and D159153.44 The dibromo starting material was
subjected to two consecutive Suzuki coupling with a variety of boronic esters and boronic acids
to obtain the final products. (Scheme 9)

Scheme 9 Synthesis of atropisomeric PDE4D partial inhibitors
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HPLC analysis of atropisomeric PDE4D partial inhibitors
The characterization of atropisomeric compounds is generally performed on analytical
HPLC systems outfitted with a chiral column as chiral stationary phase (CSPs) and selective
solvent system. A variety of synthetic or natural molecules can be used as useful CSPs. In our
case, two types of chiral columns were employed, including OD (Cellulose tris(3,5dimethylphenylcarbamate)) and AD (Amylose tris(3,5-dimethylphenylcarbamate)) column.. A
typical solvent system for enantiomeric separation is a combination of n-hexane as non-polar
mobile phase and a polar solvent such as ethanol. Having compounds prepared in methanol as 2
mM solutions, the HPLC analysis of each potential atropismeric PDE4D partial inhibitor was
performed on an Agilent 1100 system in our lab with a varying ratio of alkane and alcohol.

Figure 29 Attempted chiral separation of 50 on chiral AD column
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Figure 30 Attempted chiral separation of 54 on chiral AD column

Figure 31 Attempted chiral separation of 49 on chiral AD column
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Figure 32 Attempted chiral separation of 51 on chiral AD column

After a variety of solvent systems were tested for compounds 49-54, only 50 and 54
were successfully separated by the chiral AD column, with 30% to 35% ethanol in n-hexane
utilized as the mobile phase(Figure 29 and 30). Other compounds showed either a single or
inseparable peak with a mixture solvent of alcohol in alkane (examples shown in Figures 31
and 32). These results may be due to the halogen atom on the biaryl system, which does not
provide enough steric hindrance that contributes to the rotation barrier. On the other hand, the
methoxy group is relatively large and electron rich, which may increase the rotational barrier
allowing for the separation on analytical HPLC. Additionally, because fluorine atoms should
be considered as similar in size to protons, steric effects should not be considered as a major
factor contributing to chiral separation. To further clarify the rationale of atropisomerism in
PDE4D partial inhibitors, thermodynamic studies, such as ground and excited state energy
calculations, are necessary.
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Conclusions
Six potential atropisomeric PDE4D partial inhibitors were successfully synthesized by
the reported method and their enantiomeric properties were measured by chiral HPLC.
Although only two compounds were separated under various conditions, they still offered a
promising synthesis and analytical characterization method for the development of novel
atropismeric PDE4D partial inhibitors. Additionally, compound 50 as a racemic mixture
showed 97 nM (EC50) inhibition of cAMP via an assay performed by Dr. Mark Gurney’s group
at Tetra Discovery Partners. This indicates these novel compounds remain as active as their
precursors. Currently, we are working on obtaining each atropisomer and evaluating their
biological activities. This future work can provide us an in-depth understanding of
atropisomerism.

Experimental section
1-(4-((2',5'-dichloro-6-methoxy-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea (49)
(23 mg, 19% yield); 1H NMR (DMSO-D6, 300 MHz): δ 3.69 (s, 3H), 3.82 (s, 2H), 5.77 (s, 2HNH2), 7.00-7.04 (m, 2H), 7.08 (d, J = 8.4 Hz, 2H), 7.22 (dd, J = 8.4, 2.1 Hz, 1H), 7.28 (d, J =
8.4 Hz, 2H), 7.35 (d, J = 2.4 Hz, 1H), 7.43 (dd, J = 8.4, 2.4 Hz, 1H), 7.48 (d, J = 8.7 Hz, 1H),
8.41 (s, 1H-NH). Anal. HPLC (Ret. time: 14.3 min, Area%: 100%).
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1-(4-((5'-chloro-2-fluoro-2',6-dimethoxy-[1,1'-biphenyl]-3-yl)methyl)phenyl)urea (50)
1

H NMR (DMSO-D6, 300 MHz): δ 3.68 (d, J = 2.7 Hz, 6H), 3.81 (s, 2H), 5.77 (s, 2H-NH2),

6.85 (d, J = 8.1 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 7.09-7.24 (m, 3H), 7.29 (d, J = 8.4 Hz, 2H),
7.39 (dd, J = 9.0, 2.7 Hz, 1H), 8.42 (s, 1H-NH). Anal. HPLC (Ret. time: 13.7 min, Area%:
90%).

5-chloro-2,2'-dimethoxy-5'-(4-nitrobenzyl)-1,1'-biphenyl (51)
(104 mg, 62% yield); 1H NMR (DMSO-D6, 300 MHz): δ 3.67 (s, 6H), 4.04 (s, 2H), 7.00 (d, J =
8.4 Hz, 1H), 7.05-7.08 (m, 2H), 7.12 (d, J = 2.7 Hz, 1H), 7.22 (dd, J = 8.4, 2.1 Hz, 1H), 7.35
(dd, J = 8.7, 2.7 Hz, 1H), 7.53 (d, J = 8.7 Hz, 2H), 8.15 (d, J = 8.7 Hz, 2H). Anal. HPLC (Ret.
time: 17.6 min, Area%: 100%).

2,5-dichloro-2'-methoxy-5'-(4-nitrobenzyl)-1,1'-biphenyl (52)
(103 mg, 43% yield); 1H NMR (DMSO-D6, 500 MHz): δ 3.71 (s, 3H), 4.08 (s, 2H), 7.07 (d, J =
5.1 Hz, 1H), 7.12 (s, 1H), 7.31 (d, J = 5.1 Hz, 1H), 7.37 (s, 1H), 7.45 (d, J = 5.1 Hz, 1H), 7.54
(d, J = 5.1 Hz, 3H), 8.16 (d, J = 5.4 Hz, 2H). Anal. HPLC (Ret. time: 11.6 min, Area%: 89%).
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5-chloro-2'-methoxy-5'-(4-nitrobenzyl)-[1,1'-biphenyl]-2-carbonitrile (53)
(129 mg, 60% yield); 1H NMR (DMSO-D6, 500 MHz): δ 3.65 (s, 3H), 4.06 (s, 2H), 6.95 (d, J =
5.1 Hz, 1H), 7.18 (d, J = 5.1 Hz, 1H), 7.23 (d, J = 4.5 Hz, 1H), 7.35-7.50 (m, 2H), 7.53 (d, J =
5.1 Hz, 2H), 8.17 (d, J = 5.1 Hz, 2H).

5'-chloro-2-fluoro-2',6-dimethoxy-3-(4-nitrobenzyl)-1,1'-biphenyl (54)
(120 mg, 34% yield); 1H NMR (DMSO-D6, 300 MHz): δ 3.69 (d, J = 5.4 Hz, 6H), 4.09 (s, 2H),
6.91 (d, J = 5.1 Hz, 1H), 7.11 (d, J = 5.1 Hz, 1H), 7.16 (d, J = 1.5 Hz, 1H), 7.33-7.37 (m, 1H),
7.41 (dd, J = 5.4, 1.8 Hz, 1H), 7.49 (d, J = 5.4 Hz, 2H), 8.18 (d, J = 5.4 Hz, 2H).

CHAPTER 3

Synthesis of FOL7425 as fragment hit of MEP pathway
Our initial NMR based screening afforded three fragment hits which bind to IspD, E and
F (Chapter 1, Figure 4, FOL7093, FOL763 and FOL7425). Despite the low selectivity of these
hits, an increasing activity should be observed for them compared to the fragments only targeting
single enzyme. In order to collect the preliminary affinity of these multi-enzymes targeted
fragments, FOL 7425 was chosen for the synthetic effort. First of all, thiourea was reacted with
1, 3-dichloroacetone under rt to obtain the amino thiazole intermediate 55 as white precipitate.
Then the thiazole 55 was treated with 2-mercaptobenzoxazole and K2CO3 in anhydrous DMF
under 60 oC to afford compound 56 as FOL 7425 (Scheme 10).

Scheme 10 Synthesis of FOL 7425

SPR assay showed the KD value as 5.9 mM which indicated a reasonable binding affinity
for a fragment hit. Development on the analogs is still in progress.
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Synthesis of FOL8395 as fragment hit of MEP pathway
FOL8395 was selected for the fragment hits analysis due to its potential diversity on the
structure and a reported crystal structure (PDB: 3JVH). Future study on this chemical series will
provide us the activity of fragment itself and build a new compound library for SAR study. The
synthesis of FOL 8395 started with a nucleophilic addition of 2-(ethoxymethylene)malononitrile
and hydrazine to offer pyrazole core 57. 57 was then treated with 3-nicotinaldehyde to perform a
reductive amination. Then the cyano group was hydrolyzed by con. H2SO4 to afford compound
59 as FOL 8395 (Scheme 11).

Scheme 11 Synthesis of FOL 8395

KD value as 310 μM was observed for FOL 8395 by SPR assay. We are confident that
functionalization on the pyrazole core will afford series of potent lead compounds against IspF.
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Synthesis of imidazothiazole analogue
Similar to the fragment growing method of imidazole series, one imidazothiazole
compound was synthesized based on one known fragment hit (Chapter 1, Figure 4, FOL535).
Additionally, this imidazothiazole compound also contains part of FOL 7425 which might
provide extra information for the binging of fragment. The pre-synthesized ester of
imidazothiazole (prepared by Gashaw Goshu as a member of our research group) was treated
with LiAH4 and converted to the corresponding chloride with methanesulfonyl chloride. The
final product 62 was made by compound 61 reacted with 2-mercaptobenzoxazole (Scheme 12).

Scheme 12 Synthesis of imidazothiazole analog
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Synthesis of imidazole analogs
As described in chapter 1, a hydrophobic pocket was found close to the zinc pocket.
Derivatives create interaction with the hydrophobic pocket can potentially increase the affinity of
the lead compounds. Based on the crystal structure of fragment FOL 995, we perform a docking
analysis to construct a new series of imidazole compounds which have a high possibility to
interact with the hydrophobic pocket. Synthetic effort on these compounds was performed by
following reported methods.48,49 Imidazole core formation of aromatic isothiocyanate and 2,2dimethoxyethanamine. Compound 63 was directly reacted with aliphatic bromide to afford 65.
Compound 64 was demethylated with BBr3 then had a neucliophilic substitution with aromatic
bromide to give 67 (Scheme 13). SPR and other enzymatic assays are still in progress.

Scheme 13 Synthesis of imidazole analogs
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Scheme 13 Synthesis of imidazole analogs (continue)

Conclusions
Two fragments (FOL7425 and FOL8395) were successfully synthesized in order to
develop new chemical series targeting IspF enzyme. Additionally, fragment growing method was
applied on synthesizing imidazothiazole analog and this compound can afford extra binding
information in the future. Last but not least, a series of imidazole analogs were prepared to
evaluate their potential interactions with the hydrophobic pocket (created by Ile59, Phe63 and
Leu78) in IspF.
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Experimental section
4-(chloromethyl)thiazol-2-amine (55)
To a solution of thiourea (0.3 g, 0.0039 mol) in acetone (15 ml) was added the solution of
dichloroacetone (1 eq) in acetone (2.3 ml) dropwise. The reaction was allowed to stir overnight
under rt. Filtered the white precipitate, washed it with cold acetone and dried the solid yield
desired product 64. 1H NMR (300 MHz, DMSO-D6): δ 4.68 (s, 2H), 6.96 (s, 1H).

4-((benzo[d]oxazol-2-ylthio)methyl)thiazol-2-amine (56)
Compound 64 in 5 ml of anhydrous DMF was added 2-mercaptobenzoxazole (0.5 eq) and
K2CO3 (2 eq). Then the suspension was stirred under 60 oC overnight. TLC indicated a fully
conversion of starting materials. Extracted the reaction mixture with EtOAc (20 ml *2) and water
(20 ml), dried the organic layer and removed the solvent. Column purification with a gradient of
MeOH in DCM (100% DCM to 20% MeOH in DCM) yielded desired product 65 (0.102 g,
34%). 1H NMR (300 MHz, DMSO-D6): δ 4.43 (s, 2H), 6.56 (s, 1H), 7.04 (s, 2H), 7.31-7.35 (m,
2H), 7.64-7.67 (m, 2H); Anal. HPLC (Ret. time: 4.4 min., Area%: 99%). Anal. Calcd for
C11H9N3OS2: C, 50.17; H, 3.44; N, 15.96; Found: C, 50.12; H, 3.44; N, 15.51.

3-amino-1H-pyrazole-4-carbonitrile (57)
2-(ethoxymethylene)malononitrile (3.0 g, 0.0246 mol) in 20ml of EtOH was added hydrazine (1
eq) dropwise and the suspension was heated under reflux for 4h. The solvent was removed and
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10 ml of H2O was poured into the residue to recrystallize the product. Filtered out the remaining
solid and washed it with cold H2O (1.2 g, 45%). 1H NMR (300 MHz, DMSO-D6): δ 6.02 (s, 2H),
7.70 (s, 1H), 11.40 (br, 1H); 13C NMR (75 MHz, DMSO-D6): δ 73.88, 115.84, 139.35, 154.90.

3-((pyridin-3-ylmethyl)amino)-1H-pyrazole-4-carbonitrile (58)
Compound 66 (1.22 g, 0.011 mol) and 3-nicotinaldehyde (1 eq) in EtOH (15ml) was added
piperidine (0.1 eq) dropwise. The reaction was allowed to stir under reflux overnight. After TLC
confirmed the fully conversion of starting materials, the reaction mixture was cooled down to rt
first and then NaBH4 (2 eq) was added into the mixture. The reaction was then stirred under rt
for 2h. The solvent was removed and column purification was performed (100%EtOAc to 20%
MeOH in EtOAc) to yield desired product (1.09 g, 50%). 1H NMR (300 MHz, CD3OD): δ 4.50
(s, 2H), 7.39-7.43 (m, 1H), 7.86 (d, J = 7.8 Hz, 1H), 8.43 (d, J = 3.9 Hz, 1H), 8.55 (s, 1H). FTIR: ѵ = 2215.08 for nitrile functional group.

3-((pyridin-3-ylmethyl)amino)-1H-pyrazole-4-carboxamide (59)
Compound 67 was added con. H2SO4 (10 eq) for 20 min below 20 oC. Then the reaction mixture
was allowed to warm up to rt and stir overnight. The mixture was poured into ice and neutralized
with Na2CO3. The aqueous layer was extracted with EtOAc (20 ml*3) and the organic layers
were combined, dried and concentrated to yield desired product (0.325 g, 30%). 1H NMR (500

94

MHz, CD3OD): δ 4.51 (s, 2H), 7.41-7.43 (m, 1H), 7.86-7.88 (m, 1H), 8.43 (d, J = 5.0 Hz, 1H),
8.56 (s, 1H).

(3-methylimidazo[2,1-b]thiazol-2-yl)methanol (60)
Ethyl 3-methylimidazo[2,1-b]thiazole-2-carboxylate (0.5 g, 0.0024 mol) in anhydrous THF (15
ml) was added LiAH4 propotionally under 0 oC. The reaction mixture was then stirred for 3h
under rt and with TLC monitoring the conversion of starting material. The reaction mixture was
extracted with (chloroform:MeOH = 3:1, 30ml*2) and saturated NH4Cl(30 ml). The organic
layers were combined and dried to obtain desired product (0.272 g, 67%). 1H NMR (300 MHz,
DMSO-D6): δ 2.35 (s, 3H), 4.56 (d, J = 5.4 Hz, 2H), 5.55 (t, J = 5.4 Hz, 1H-OH), 7.22 (d, J = 1.5
Hz, 1H), 7.68 (d, J = 1.2 Hz, 1H).

2-(chloromethyl)-3-methylimidazo[2,1-b]thiazole (61)
Compound 69 (0.25 g, 0.0015 mol) in dry DCM (10 ml) was added Et3N (1.2 eq) and then
methanesulfonyl chloride (1.2 eq) under 0 oC. The reaction was warmed up to rt and stirred
overnight. Extraction was performed for the reaction mixture with EtOAc (20 ml*2) and H2O
(20 ml). The organic layers were combined, dried and concentrated to yield desired product with
quantitative yield. 1H NMR (500 MHz, DMSO-D6): δ 2.48 (s, 3H), 5.10 (s, 1H), 7.34 (s, 1 H),
7.81 (s, 1H).
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2-(((3-methylimidazo[2,1-b]thiazol-2-yl)methyl)thio)benzo[d]oxazole (62)
Compound 70 (0.173 g, 0.00093 mol) in anhydrous DMF was added K2CO3 and 2mercaptobenzoxazole (1 eq). The reaction mixture was heated under 60 oC overnight. The
mixture was then extracted with EtOAc (20 ml *3), H2O (20 ml*2) and brine (20 ml). The
organic layers were combined, dried and then column purification was performed (100% DCM
to 20% MeOH in DCM) to obtain desired product (0.08 g, 29%). 1H NMR (300 MHz, CDCl3): δ
2.56 (s, 3H), 4.68 (s, 2H), 7.28-7.35 (m, 3H), 7.40 (s, 1H), 7.46-7.49 (m, 1H), 7.62-7.65 (m, 1H).
Anal. HPLC (Ret. time: 6.8 min., Area%: > 99%). Anal. Calcd for C14H11N3OS2 • 0.2 EtOAc: C,
55.72; H, 3.98; N, 13.17; Found: C, 55.98; H, 3.82; N, 13.12.

1-phenyl-1H-imidazole-2(3H)-thione (63)
Isothiocyanatobenzene (0.3 g, 0.0022 mol) was dissolved in toluene (5 ml) and then 2,2dimethoxyethanamine (1 eq) was added dropwise into the toluene solution. The mixture was
stirred under rt for 1h. Then con. HCl was added and reaction was stirred under reflux for 3h.
The solvent was removed and 5 ml of H2O was added. The PH of solution was adjusted to 8 by
1M NaOH. The precipitate was filtered out and dried to yield desired product (0.261 g, 67%).

1-(4-methoxyphenyl)-1H-imidazole-2(3H)-thione (64)
1-isothiocyanato-4-methoxybenzene (1.0 g, 0.006 mol) was dissolved in toluene (5 ml) and then
2,2-dimethoxyethanamine (1 eq) was added dropwise into the toluene solution. The mixture was
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stirred under rt for 1h. Then con. HCl was added and reaction was stirred under reflux for 3h.
The solvent was removed and 5 ml of H2O was added. The PH of solution was adjusted to 8 by
1M NaOH. The precipitate was filtered out and dried to yield desired product (0.5 g, 61%). 1H
NMR (300 MHz, CDCl3): δ 3.87 (s, 3H), 6.89 (br, 2H), 7.02 (d, J = 9 Hz, 2H), 7.50 (d, J = 9 Hz,
2H); 13C NMR (75 MHz, CDCl3): 55.57, 114.37, 114.88, 119.91, 126.09, 127.33, 130.31.

Ethyl 2-((1-phenyl-1H-imidazol-2-yl)thio)acetate (65)
Compound 72 (0.256 g, 0.0015 mol) was dissolved in EtOH (5 ml) and ethyl 2-bromoacetate (1
eq), Et3N (1 eq) were added. The reaction mixture was heated under reflux for 3h and then
extracted with EtOAc (20 ml*2) and H2O (20 ml). The organic layers were combined, dried and
concentrated to yield desired product (0.292 g, 77%). 1H NMR (300 MHz, CDCl3): δ 1.25 (t, J =
7.2 Hz, 3H), 3.98 (s, 2H), 4.17 (q, J = 7.2 Hz, 2H), 7.15 (d, J = 1.2 Hz, 1H), 7.20 (d, J = 1.5 Hz,
1H), 7.40-7.51 (m, 5H).

1-(4-hydroxyphenyl)-1H-imidazole-2(3H)-thione (66)
Compound 73 (0.81 g, 0.0039 mol) in anhydrous DCM (20 ml) was cooled down to -70 oC and
then BBr3 solution (12 ml) was added dropwise into the solution. The reaction was then warmed
up to rt and stirred for 2h. Poured 20 ml of H2O into the reaction mixture and filtered out the
precipitate as desired product (0.463 g, 62%). 1H NMR (300 MHz, CD3OD): δ 6.89 (d, J = 8.7
Hz, 2H), 6.96 (d, J = 2.4 Hz, 1H), 7.06 (d, J = 2.4 Hz, 1H), 7.34 (d, J = 8.7 Hz, 2H).
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4-(2-((4-chlorobenzyl)thio)-1H-imidazol-1-yl)phenol (67)
Compound 75 (0.1 g, 0.00052 mol) was dissolved in EtOH (3 ml) and 1-(bromomethyl)-4chlorobenzene (1 eq), Et3N (1 eq) were added into the solution. The reaction mixture was then
heated under reflux for 3h. The mixture was extracted with EtOAc (20 ml*2) and H2O (20 ml).
The organic layers were combined, dried and concentrated to yield desired product (0.123 g,
75%). 1H NMR (300 MHz, CD3OD): δ 4.03 (s, 2H), 6.79 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 9.0 Hz,
2H), 7.01 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 1.2 Hz, 1H), 7.19 (d, J = 8.7 Hz, 2H), 7.22 (d, J = 1.5
Hz, 1H).
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H NMR and 13C NMR SPECTRA of IMIDAZOLE COMPOUNDS
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H NMR and 13C NMR SPECTRA of PYRIMIDINE COMPOUNDS
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H NMR and 13C NMR SPECTRA of D159687, D159404, D159153
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